Target Information

General Information of This Target

Target ID	PATR0EGDKN
Target Name	DNA topoisomerase 1 (TOP1)
Gene Name	TOP1
Gene ID	7150
Synonym	DNA topoisomerase I
Sequence	MSGDHLHNDSQIEADFRLNDSHKHKDKHKDREHRHKEHKKEKDREKSKHSNSEHKDSEKK HKEKEKTKHKDGSSEKHKDKHKDRDKEKRKEEKVRASGDAKIKKEKENGFSSPPQIKDEP EDDGYFVPPKEDIKPLKRPRDEDDADYKPKKIKTEDTKKEKKRKLEEEEDGKLKKPKNKD KDKKVPEPDNKKKKPKKEEEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYEPLPENVKF YYDGKVMKLSPKAEEVATFFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKNIITNLSKC DFTQMSQYFKAQTEARKQMSKEEKLKIKEENEKLLKEYGFCIMDNHKERIANFKIEPPGL FRGRGNHPKMGMLKRRIMPEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTWLVSWTENI QGSIKYIMLNPSSRIKGEKDWQKYETARRLKKCVDKIRNQYREDWKSKEMKVRQRAVALY FIDKLALRAGNEKEEGETADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGKDSIRYYNK VPVEKRVFKNLQLFMENKQPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTYNASITLQQ QLKELTAPDENIPAKILSYNRANRAVAILCNHQRAPPKTFEKSMMNLQTKIDAKKEQLAD ARRDLKSAKADAKVMKDAKTKKVVESKKKAVQRLEEQLMKLEVQATDREENKQIALGTSK LNYLDPRITVAWCKKWGVPIEKIYNKTQREKFAWAIDMADEDYEF Click to Show/Hide
Family	the type IB topoisomerase family
Function	Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)- enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the BMAL1 promoter. Click to Show/Hide
Uniprot Entry	TOP1_HUMAN
HGNC ID	HGNC:11986
KEGG ID	hsa:7150

Full List of The ADC Related to This Target

Approved in 2025

Click To Hide/Show 5 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	Trastuzumab rezetecan	Trastuzumab	HER2	SHR9265	Mc-Gly-Gly-Phe-Gly	[2]
ADC Info	Datopotamab deruxtecan	Datopotamab	TROP2	DXd	Mc-Gly-Gly-Phe-Gly
ADC Info	Trastuzumab deruxtecan	Trastuzumab	HER2	DXd	Mc-Gly-Gly-Phe-Gly	[3]
ADC Info	Sacituzumab govitecan	Sacituzumab	TROP2	SN-38	CL2A	[4]
ADC Info	Sacituzumab tirumotecan	Sacituzumab	TROP2	KL610023	Pyrimidine CL2A carbonate linker

New Drug Application

Click To Hide/Show 19 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker
ADC Info	Patritumab deruxtecan	Patritumab	HER3	DXd	Mc-Gly-Gly-Phe-Gly
ADC Info	Ifinatamab deruxtecan	Ifinatamab	B7-H3	DXd	Mc-Gly-Gly-Phe-Gly
ADC Info	Trastuzumab pamirtecan	BAT-0606	HER2	P1003	Mc-Gly-Gly-Phe-Gly
ADC Info	ESG401	Anti-TROP2 IgG1 mAb	TROP2	SN-38	A proprietary stable-cleavable linker
ADC Info	Trastuzumab bultecan	Trastuzumab	HER2	NT1	PODS-CHX-A"-DTPA
ADC Info	Rinatabart sesutecan	Rinatabart	FRα	Exatecan	T1000
ADC Info	Garetatug rezetecan	Garetatug	CLDN18.2	SHR9265	Mc-Gly-Gly-Phe-Gly
ADC Info	Trastuzumab brengitecan	Trastuzumab	HER2	Ed-04	Gly-Mal-Gly-Gly-Phe-Gly
ADC Info	FDA018	Anti-Trop-2 mAb	TROP2	SN-38	An acid-cleavable linker
ADC Info	GQ1005	Trastuzumab variant	HER2	DXd	Mc-Gly-Gly-Phe-Gly (ring-opening derivative)
ADC Info	Mocertatug rezetecan	Mocertatug	B7-H4	SHR9265	Mc-Gly-Gly-Phe-Gly
ADC Info	Risvutatug rezetecan	Risvutatug	B7-H3	SHR9265	Mc-Gly-Gly-Phe-Gly
ADC Info	Arcotatug tavatecan	Anti-CLDN18.2 mAb	CLDN18.2	Exatecan	Synaffix linker
ADC Info	Anbenitamab repodatecan	Anbenitamab	HER2	DXd	DBCO-PEG4-Mc-Gly-Gly-Phe-Gly
ADC Info	Ruzaltatug rezetecan	Ruzaltatug	HER3	SHR9265	Mc-Gly-Gly-Phe-Gly
ADC Info	Notiretatug rezetecan	Anti-Nectin-4 antibody	nectin-4	SHR9265	Mc-Gly-Gly-Phe-Gly
ADC Info	Tambotatug pelitecan	Tambotatug	B7-H3	YL0010014	VK*G-NHCH2-O linker
ADC Info	SYS6010	Anti-EGFR antibody	EGFR	JS-1	Mc-Gly-Gly-Phe-Gly
ADC Info	telisotuzumab adizutecan	Telisotuzumab	c-Met	AMDCPT	Adizutecan linker

Phase 3

Click To Hide/Show 4 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker
ADC Info	Tizetatug rezetecan	Tizetatug	TROP2	SHR9265	Mc-Gly-Gly-Phe-Gly
ADC Info	TQB2102	Anti-HER2 antibody	HER2	2-DDDX-d	Mc-Gly-Gly-Phe-Gly
ADC Info	HLX43	HLX20	PDL1	YL0010014	VK*G-NHCH2-O linker
ADC Info	JSKN-016	Anti-HER3/TROP2 bsAb	HER3; TROP2	TOP1 inhibitor	A cleavable linker

Phase 2 (discontinued)

Click To Hide/Show 1 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	Labetuzumab govitecan	Labetuzumab	CEACAM5	SN-38	CL2A

Phase 3

Click To Hide/Show 24 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	Puxitatug samrotecan	Puxitatug	B7-H4	AZ14170132 (AZ0132)	Mal-PEG8-Val-Ala
ADC Info	Sacituzumab drozuntecan	Anti-TROP2 antibody	TROP2	P1021	Mc-Gly-Gly-Phe-Gly
ADC Info	MHB088C	Anti-B7H3 antibody	B7-H3	MH30010008	A cleavable linker
ADC Info	PRO1160	Anti-CD70 antibody	CD70	Exatecan	T1000
ADC Info	XNW27011	Anti-CLDN18.2 antibody	CLDN18.2	YL0010014	VK*G-NHCH2-O linker
ADC Info	Torvutatug samrotecan	Torvutatug	FRα	AZ14170132 (AZ0132)	Mal-PEG8-Val-Ala
ADC Info	MHB036C	Anti-TROP2 antibody	TROP2	MH30010008	Stable cleavable linker
ADC Info	BL-M02D1	Hu4D3	TROP2	Ed-04	Cathepsin B cleavable linker
ADC Info	Precemtabart tocentecan	Precemtabart	CEACAM5	Exatecan	Mal-glucuronide-PABC
ADC Info	SKB410	Anti-Nectin-4 antibody	nectin-4	TOP1 inhibitor	Undisclosed
ADC Info	TUB-030	Anti-5T4 antibody	5T4	Exatecan	P5 (PEG24)-Val-Cit-PABC
ADC Info	9MW2921	Anti-TROP2 antibody	TROP2	Mtoxin	A cleavable linker	[5]
ADC Info	TUB-040	Anti-Napi2b Fc-silenced IgG1 mAb	NaPi-2b	Exatecan	P5 (PEG24)-Val-Cit-PABC
ADC Info	GQ1010	Anti-TROP2 antibody	TROP2	Camptothecin analog	A cleavable open-ring linker
ADC Info	OBI-992	R4702	TROP2	Exatecan	Mal-PEG24-Val-Ala-PABC
ADC Info	DS-3939	Gatipotuzumab	Muc1	DXd	Mc-Gly-Gly-Phe-Gly
ADC Info	DB-1311	Anti-B7H3 antibody	B7-H3	P1021	Mc-Gly-Gly-Phe-Gly
ADC Info	DB-1310	Anti-HER3 IgG1 mAb	HER3	P1021	Mc-Gly-Gly-Phe-Gly
ADC Info	DB-1419	Anti-B7H3/PDL1 bsAb	B7-H3; PDL1	P1003	A tetra-peptide based cleavable linker
ADC Info	PRO-1286	Anti-EGFR/c-Met bsAb	EGFR; c-Met	Exatecan	T1000
ADC Info	Lixarkitug samrotecan	INT016	CD123	AZ14170132 (AZ0132)	Mal-PEG8-Val-Ala
ADC Info	YL205	Anti-NaPi2b mAb	NaPi-2b	YL0010014	VK*G-NHCH2-O linker
ADC Info	AMT-253	Anti-MUC18 IgG1 mAb	Muc18	Exatecan	T1000
ADC Info	AMT-116	Anti-CD44v9 antibody	CD44v9	KL610023	Hydrolysable linker

Phase 2

Click To Hide/Show 42 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	FDA022	Trastuzumab	HER2	DXd	Mc-Val-Ala-PABC double self-immolative linker	[6]
ADC Info	BAT8007	Anti-Nectin-4 antibody	nectin-4	Exatecan	A cleavable but systemically stable linker
ADC Info	BAT8008	Anti-TROP2 antibody	TROP2	Exatecan	Maleimide tetrapeptide-based cleavable linker
ADC Info	BAT8006	Anti-FRα antibody	FRα	Exatecan	A cleavable linker
ADC Info	BAT8009	Anti-B7H3 antibody	B7-H3	Exatecan	A cleavable linker
ADC Info	BAT8010	Anti-HER2 antibody	HER2	Exatecan	A cleavable linker
ADC Info	SHR-A1912	SHR-1920	CD79b	SHR9265	Mc-Gly-Gly-Phe-Gly
ADC Info	SKB315	Anti-CLDN18.2 antibody	CLDN18.2	Belotecan-derivative	Kthiol (pyrimidine-thiol) oligopeptide linker
ADC Info	YL202	Anti-HER3 IgG1 mAb	HER3	YL0010014	VK*G-NHCH2-O linker
ADC Info	Tilatamig samrotecan	Tilatamig	EGFR; c-Met	AZ14170132 (AZ0132)	Mal-PEG8-Val-Ala
ADC Info	TQB2103	Anti-CLDN18.2 IgG1 mAb	CLDN18.2	2-DDDX-d	A cleavable linker
ADC Info	BL-M11D1	Gemtuzumab	CD33	Ed-04	Gly-Mal-Gly-Gly-Phe-Gly
ADC Info	FZ-AD004	Anti-TROP2 antibody	TROP2	DXd	Mc-Val-Ala-PABC double self-immolative linker
ADC Info	ZL-1310	Undisclosed	Delta-like protein 3 (DLL3)	YL0010014	Tumor microenviroment activable tripeptide linker	[7]
ADC Info	BL-M08D1	Anti-TROP2 antibody	TROP2	Ed-04	Gly-Mal-Gly-Gly-Phe-Gly
ADC Info	BL-M05D1	5103F3	CLDN18.2	Ed-04	Gly-Mal-Gly-Gly-Phe-Gly
ADC Info	HLX42	Anti-EGFR IgG1 mAb	EGFR	TOP1 inhibitor	A cleavable linker
ADC Info	PHN-010	undisclosed	Undisclosed	TOP1 inhibitor	Undisclosed
ADC Info	AMT-676	Anti-CDH17 antibody	CDH17	Exatecan	T1000
ADC Info	HBM9033	Anti-MSLN antibody	MSLN	YL0010014	VK*G-NHCH2-O linker
ADC Info	DXC006	DXA006	CD56	CPT113	A cleavable peptide linker
ADC Info	BG-C9074	Anti-B7H4 antibody	B7-H4	TOP1 inhibitor	A cleavable linker
ADC Info	Varsetatug masetecan	Varsetatug	EpCAM	CAMP59	L-ala-ala-ala (TAL)
ADC Info	DM002	Anti-HER3/Muc1 bsAb	HER3; Muc1	BCPT02	Hydrophilic, protease-cleavable linker
ADC Info	DM001	Anti-EGFR/TROP2 bsAb	EGFR; TROP2	BCPT02	Hydrophilic, protease-cleavable linker
ADC Info	AMT-707	Anti-CDH6 IgG1 mAb	CDH6	Exatecan	T1000
ADC Info	ZW191	Anti-FOLR1 IgG1 mAb	FRα	ZD06519	Mc-Gly-Gly-Phe-Gly-AM
ADC Info	ADRX-0405	Anti-STEAP1 antibody	STEAP1	AP052	A cleavable linker
ADC Info	DXC1002	Anti-TROP2 antibody	TROP2	CPT113	CrossConju linker
ADC Info	AMT-562	Ab562	HER3	Exatecan	T800
ADC Info	SGN-CEACAM5C	Tusamitamab	CEACAM5	AMDCPT	A cleavable linker
ADC Info	IBI3001	IBI-334	B7-H3; EGFR	Exatecan	Undisclosed
ADC Info	IBI3005	Anti-EGFR/HER3 bsAb	EGFR; HER3	NT1	Undisclosed
ADC Info	ABBV-969	Anti-PSMA/STEAP1 IgG1 mAb	PSMA; STEAP1	A-1770637	BrAc-Val-Ala
ADC Info	DM005	Anti-EGFR/c-Met bsAb	EGFR; c-Met	BCPT02	Hydrophilic, protease-cleavable linker
ADC Info	Turmetabart adizutecan	Anti-SEZ6 antibody	SEZ6	A-1770637	BrAc-Val-Ala
ADC Info	IPH45	Anti-Nectin-4 antibody	nectin-4	Exatecan	A cleavable hydrophilic linker
ADC Info	YL211	Anti-c-Met antibody	c-Met	YL0010014	VK*G-NHCH2-O linker
ADC Info	LY4101174	Anti-Nectin-4 antibody	nectin-4	Exatecan	maleimide-β-glucuronide poly-sarcosine linker
ADC Info	LY4052031	Anti-Nectin-4 IgG1 Fc-silent mAb	nectin-4	LSN3889710	A cleavable peptide linker
ADC Info	SHR-4849	SHR-2495	DLL3	SHR9265	Mc-Gly-Gly-Phe-Gly
ADC Info	SHR-1826	Anti-c-MET IgG2 mAb	c-Met	SHR9265	Mc-Gly-Gly-Phe-Gly

Phase 1 (discontinued)

Click To Hide/Show 1 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	DS-6157	Anti-GPR20 antibody	GPR20	DXd	Mc-Gly-Gly-Phe-Gly

Investigative

Click To Hide/Show 170 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	H01L02-DXd	Anti-CDH6 mAb H01L02	Cadherin-6 (CDH6)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[8]
ADC Info	H02L02-DXd	Anti-CDH6 mAb H02L02	Cadherin-6 (CDH6)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[8]
ADC Info	H02L03-DXd	Anti-CDH6 mAb H02L03	Cadherin-6 (CDH6)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[8]
ADC Info	H04L02-DXd	Anti-CDH6 mAb H04L02	Cadherin-6 (CDH6)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[8]
ADC Info	NOV0712-DXd	Anti-CDH6 mAb NOV0712	Cadherin-6 (CDH6)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[8]
ADC Info	XB371	Anti-tissue factor antibody	tissue factor	Belotecan	A cleavable linker	[9]
ADC Info	7MW3711	Anti-B7H3 antibody	B7-H3	Mtoxin	A cleavable linker	[10]
ADC Info	CAC10-CPT-LB	Brentuximab	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)	Methylenedioxy CPT2 (CPT2)	Mc-PEG4-Val-Lys-Gly	[11]
ADC Info	CAC10-CPT-LC	Brentuximab	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)	Methylenedioxy CPT2 (CPT2)	Mc-PEG8-Val-Lys-Gly	[11]
ADC Info	H00-CPT-LC	Anti-CD30 mAb h00	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)	Methylenedioxy CPT2 (CPT2)	Mc-PEG8-Val-Lys-Gly	[11]
ADC Info	CAC10-DT	Brentuximab	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[11]
ADC Info	CAC10-GT	Brentuximab	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)	Active metabolite of irinotecan SN38	CL2A	[11]
ADC Info	Mil40-5	Mil40	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Active metabolite of irinotecan SN38	Mc-Val-Ala-PABC	[12]
ADC Info	Mil40-6	Mil40	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Active metabolite of irinotecan SN38	Mal-PEG2-Val-Ala-PABC	[12]
ADC Info	Mil40-7	Mil40	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Active metabolite of irinotecan SN38	Mal-PEG4-Val-Ala-PABC	[12]
ADC Info	Mil40-8	Mil40	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Active metabolite of irinotecan SN38	Mal-PEG8-Val-Ala-PABC	[12]
ADC Info	40H3-CL2A-SN38	Anti-EGFR mAb 40H3	Epidermal growth factor receptor (EGFR)	Active metabolite of irinotecan SN38	CL2A	[13]
ADC Info	40H3-Deruxtecan	Anti-EGFR mAb 40H3	Epidermal growth factor receptor (EGFR)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[13]
ADC Info	Lmab-CL2A-SN38	Labetuzumab	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	Active metabolite of irinotecan SN38	CL2E	[14]
ADC Info	Emab-CL2E-SN38	Epratuzumab	B-cell receptor CD22 (CD22)	Active metabolite of irinotecan SN38	CL2E	[14]
ADC Info	N501-SN38	Anti-5T4 n501 (nanobody)	Trophoblast glycoprotein (TPBG)	Active metabolite of irinotecan SN38	CL2A	[15]
ADC Info	M603-SN38 DAR6	Anti-5T4 mAb m603	Trophoblast glycoprotein (TPBG)	Active metabolite of irinotecan SN38	CL2A	[15]
ADC Info	CAC10-CPT-LA	Brentuximab	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)	Methylenedioxy CPT1 (CPT1)	Mc-PEG4-Val-Lys-Gly	[11]
ADC Info	H00-CPT-LA	Anti-CD30 mAb h00	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)	Methylenedioxy CPT1 (CPT1)	Mc-PEG4-Val-Lys-Gly	[11]
ADC Info	H00-CPT-LB	Anti-CD30 mAb h00	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)	Methylenedioxy CPT2 (CPT2)	Mc-PEG4-Val-Lys-Gly	[11]
ADC Info	H00-DT	Anti-CD30 mAb h00	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[11]
ADC Info	H00-GT	Anti-CD30 mAb h00	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)	Active metabolite of irinotecan SN38	CL2A	[16]
ADC Info	Zocilurtatug pelitecan	Zocilurtatug	DLL3	YL0010014	VK*G-NHCH2-O linker	[17]
ADC Info	BL-M14D1	Anti-DLL3 mAb	DLL3	Ed-04	Gly-Mal-Gly-Gly-Phe-Gly	[18]
ADC Info	HB0052	Anti-CD73 antibody	CD73	SN-38	A cleavable linker	[19]
ADC Info	DXC-014	Anti-B7H3/PSMA bsAb	B7-H3; PSMA	TOP1 inhibitor	Undisclosed	[20]
ADC Info	DpADC	Undisclosed	Tumor-associated calcium signal transducer 2 (TACSTD2)	Topo1 inhibitor+immune agonist	Undisclosed	[21]
ADC Info	HER2 targeted DEP conjugate	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Active metabolite of irinotecan SN38	Undisclosed	[22]
ADC Info	VL-DAB31-SN38	Rabbit derived VL single-domain Anti-ody	Undisclosed	Active metabolite of irinotecan SN38	Mal-Cyc-PEG3-DAB	[23]
ADC Info	ROS-responsive SN38 ADC	Rabbit derived VL single-domain Anti-ody	Undisclosed	Active metabolite of irinotecan SN38	Mal-Cyc-PEG3-DAB	[23]
ADC Info	HLL1-CL2A-SN38	Milatuzumab	HLA class II histocompatibility antigen gamma chain (CD74)	Active metabolite of irinotecan SN38	CL2A	[24]
ADC Info	Mil40-11 (DAR=7.1)	Mil40	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Active metabolite of irinotecan SN38	Mc-PEG8-Val-Ala-PABC	[12]
ADC Info	Mil40-11 (DAR=3.8)	Mil40	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Active metabolite of irinotecan SN38	Mc-PEG8-Val-Ala-PABC	[12]
ADC Info	M603-SN38 DAR8	Anti-5T4 mAb m603	Trophoblast glycoprotein (TPBG)	Active metabolite of irinotecan SN38	CL2A	[15]
ADC Info	M603-SN38 DAR4	Anti-5T4 mAb m603	Trophoblast glycoprotein (TPBG)	Active metabolite of irinotecan SN38	CL2A	[15]
ADC Info	IMMU-140	IMMU-114	HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA)	Active metabolite of irinotecan SN38	CL2A	[25]
ADC Info	HPAM4-CL2A-SN38	Anti-MUC1 mAb hPAM4	Mucin-1 (MUC1)	Active metabolite of irinotecan SN38	CL2A	[26]
ADC Info	HA19-SN38 antibody-drug conjugate	Anti-CD19 mAb hA19	B-lymphocyte antigen CD19 (CD19)	Active metabolite of irinotecan SN38	CL2A	[27]
ADC Info	A7R-ADC-SN38	Anti-IL7R mAb A7R	Interleukin-7 receptor subunit alpha (IL7R)	Active metabolite of irinotecan SN38	Mal-PEG12-carbamate-PEG27	[28]
ADC Info	Raludotatug deruxtecan	Raludotatug	CDH6	DXd	Mc-Gly-Gly-Phe-Gly	[29]
ADC Info	SMP-190	Undisclosed	Undisclosed	DX-8951 derivative (DXd)	Unique hydrophilic Linker	[30]
ADC Info	PRO-1102	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Exatecan	Cleavable hydrophilic linker	[31]
ADC Info	Tra-Exa-PSAR10	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Exatecan	Mal-Exa-PSAR10	[32]
ADC Info	Tra-Exa-PSAR0	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Exatecan	Mal-Exa-PSAR0	[32]
ADC Info	STRO-003	SP11285	Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)	Exatecan	SC3417	[33]
ADC Info	HMBD-501	Anti-HER3 mAb	HER3	Exatecan	A cleavable linker	[34]
ADC Info	NV104	Undisclosed	CD276 antigen (CD276)	Irinotecan	Undisclosed	[35]
ADC Info	NV103	Undisclosed	CD99 antigen (CD99)	Irinotecan	Undisclosed	[36]
ADC Info	DAN-311	Undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Camptothecin	Undisclosed	[37]
ADC Info	ZW251	Anti-GPC3 antibody	GPC3	ZD06519	Mc-Gly-Gly-Phe-Gly-AM	[38]
ADC Info	ZW-220	Fully humanized Anti-SLC34A2 IgG1 mAb	Sodium-dependent phosphate transport protein 2B (SLC34A2)	ZD06519	Mc-Gly-Gly-Phe-Gly-AM	[39]
ADC Info	AMB-101	Undisclosed	Undisclosed	Topoisomerase I inhibitor	Undisclosed	[40]
ADC Info	STRO-004	Anti-tissue factor mAb	tissue factor	Exatecan	A cleavable linker	[41]
ADC Info	SIBP-A13	Anti-HER3 mAb	HER3	DXd	Mc-VASGFG	[42]
ADC Info	Trastuzumab-L6	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	MF-6	Bridged PEG4-valine-alanine	[43]
ADC Info	Trastuzumab-T1000-exatecan	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Exatecan	Undisclosed	[44]
ADC Info	Cot-APTEDB-SN38	Anti-EDB Ab cot	Vesicle-associated membrane protein 8 (VAMP8)	Active metabolite of irinotecan SN38	Mal-PEG4-Ala	[45]
ADC Info	ADC1-2	Cofetuzumab	Inactive tyrosine-protein kinase 7 (PTK7)	ADC 1-2 payload	ADC 1-2 linker	[46]
ADC Info	ADC1-4	Cofetuzumab	Inactive tyrosine-protein kinase 7 (PTK7)	ADC 1-4 payload	ADC 1-4 linker	[46]
ADC Info	ADC1-11	Cofetuzumab	Inactive tyrosine-protein kinase 7 (PTK7)	ADC 1-11 payload	ADC 1-11 linker	[46]
ADC Info	ADC2-2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-2 payload	ADC 2-2 linker	[46]
ADC Info	ADC2-4	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-4 payload	ADC 2-4 linker	[46]
ADC Info	ADC2-6-2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-6-2 payload	ADC 2-6-2 linker	[46]
ADC Info	ADC2-7-2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-7-2 payload	ADC 2-7-2 linker	[46]
ADC Info	ADC2-9-1	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-9-1 payload	ADC 2-9-1 linker	[46]
ADC Info	ADC2-9-2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-9-2 payload	ADC 2-9-2 linker	[46]
ADC Info	ADC2-10	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-10 payload	ADC 2-10 linker	[46]
ADC Info	ADC2-11	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-11 payload	ADC 2-11 linker	[46]
ADC Info	ADC2-22	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-22 payload	ADC 2-22 linker	[46]
ADC Info	ADC2-23	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-23 payload	ADC 2-23 linker	[46]
ADC Info	ADC2-24	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-24 payload	ADC 2-24 linker	[46]
ADC Info	ADC2-25	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-25 payload	ADC 2-25 linker	[46]
ADC Info	ADC2-26	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-26 payload	ADC 2-26 linker	[46]
ADC Info	ADC2-27	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-27 payload	ADC 2-27 linker	[46]
ADC Info	ADC2-29	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-29 payload	ADC 2-29 linker	[46]
ADC Info	ADC2-30	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-30 payload	ADC 2-30 linker	[46]
ADC Info	ADC2-31	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-31 payload	ADC 2-31 linker	[46]
ADC Info	ADC2-32	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-32 payload	ADC 2-32 linker	[46]
ADC Info	ADC2-33	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-33 payload	ADC 2-33 linker	[46]
ADC Info	ADC2-34	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-34 payload	ADC 2-34 linker	[46]
ADC Info	ADC2-35	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-35 payload	ADC 2-35 linker	[46]
ADC Info	ADC2-36-1	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-36-1 payload	ADC 2-36-1 linker	[46]
ADC Info	ADC2-36-2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-36-2 payload	ADC 2-36-2 linker	[46]
ADC Info	ADC2-37	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-37 payload	ADC 2-37 linker	[46]
ADC Info	ADC2-38	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-38 payload	ADC 2-38 linker	[46]
ADC Info	ADC2-39	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-39 payload	ADC 2-39 linker	[46]
ADC Info	ADC2-40	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-40 payload	ADC 2-40 linker	[46]
ADC Info	ADC2-41	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-41 payload	ADC 2-41 linker	[46]
ADC Info	ADC2-42	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-42 payload	ADC 2-42 linker	[46]
ADC Info	ADC2-42-RO	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-42-RO payload	ADC 2-42-RO linker	[46]
ADC Info	ADC2-43	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-43 payload	ADC 2-43 linker	[46]
ADC Info	ADC2-44	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-44 payload	ADC 2-44 linker	[46]
ADC Info	ADC2-45	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-45 payload	ADC 2-45 linker	[46]
ADC Info	ADC2-46	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-46 payload	ADC 2-46 linker	[46]
ADC Info	ADC2-47	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-47 payload	ADC 2-47 linker	[46]
ADC Info	ADC2-48	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-48 payload	ADC 2-48 linker	[46]
ADC Info	ADC2-49	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-49 payload	ADC 2-49 linker	[46]
ADC Info	ADC2-50	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-50 payload	ADC 2-50 linker	[46]
ADC Info	ADC2-51	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-51 payload	ADC 2-51 linker	[46]
ADC Info	ADC2-53	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-53 payload	ADC 2-53 linker	[46]
ADC Info	ADC2-54	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-54 payload	ADC 2-54 linker	[46]
ADC Info	ADC2-55	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-55 payload	ADC 2-55 linker	[46]
ADC Info	ADC2-56	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-56 payload	ADC 2-56 linker	[46]
ADC Info	ADC2-57	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-57 payload	ADC 2-57 linker	[46]
ADC Info	ADC2-58	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-58 payload	ADC 2-58 linker	[46]
ADC Info	ADC2-59	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-59 payload	ADC 2-59 linker	[46]
ADC Info	ADC2-60	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-60 payload	ADC 2-60 linker	[46]
ADC Info	ADC2-61	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-61 payload	ADC 2-61 linker	[46]
ADC Info	ADC-2-62-1	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-62-1 payload	ADC 2-62-1 linker	[46]
ADC Info	ADC-2-62-2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-62-2 payload	ADC 2-62-2 linker	[46]
ADC Info	ADC-2-63-1	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-63-1 payload	ADC 2-63-1 linker	[46]
ADC Info	ADC-2-63-2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-63-2 payload	ADC 2-63-2 linker	[46]
ADC Info	ADC-2-64-1	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-64-1 payload	ADC 2-64-1 linker	[46]
ADC Info	ADC-2-64-2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-64-2 payload	ADC 2-64-2 linker	[46]
ADC Info	ADC-2-65-1	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-65-1 payload	ADC 2-65-1 linker	[46]
ADC Info	ADC-2-65-2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-65-2 payload	ADC 2-65-2 linker	[46]
ADC Info	ADC3-1	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 3-1 payload	ADC 3-1 linker	[46]
ADC Info	ADC3-2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 3-2 payload	ADC 3-2 linker	[46]
ADC Info	ADC3-3	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 3-3 payload	ADC 3-3 linker	[46]
ADC Info	ADC3-4	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 3-4 payload	ADC 3-4 linker	[46]
ADC Info	ADC3-5	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 3-5 payload	ADC 3-5 linker	[46]
ADC Info	ADC3-6	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-6 payload	ADC 3-6 linker	[46]
ADC Info	ADC3-7	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-7 payload	ADC 3-7 linker	[46]
ADC Info	ADC3-8	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-8 payload	ADC 3-8 linker	[46]
ADC Info	ADC3-9	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-9 payload	ADC 3-9 linker	[46]
ADC Info	ADC3-10	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-10 payload	ADC 3-10 linker	[46]
ADC Info	ADC3-11	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-11 payload	ADC 3-11 linker	[46]
ADC Info	ADC3-12	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-12 payload	ADC 3-12 linker	[46]
ADC Info	ADC3-13	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-13 payload	ADC 3-13 linker	[46]
ADC Info	ADC3-14	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-14 payload	ADC 3-14 linker	[46]
ADC Info	ADC3-15	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-15 payload	ADC 3-15 linker	[46]
ADC Info	ADC3-16	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-16 payload	ADC 3-16 linker	[46]
ADC Info	ADC3-17	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-17 payload	ADC 3-17 linker	[46]
ADC Info	ADC3-18	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-18 payload	ADC 3-18 linker	[46]
ADC Info	ADC3-19	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-19 payload	ADC 3-19 linker	[46]
ADC Info	ADC3-20	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC 3-20 payload	ADC 3-20 linker	[46]
ADC Info	ADC-C2	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC-C2 payload	ADC-C2 linker	[46]
ADC Info	ADC-C3	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC-C3 payload	ADC-C3 linker	[46]
ADC Info	ADC-C4	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC-C4 payload	ADC-C4 linker	[46]
ADC Info	ADC-C5	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC-C5 payload	ADC-C5 linker	[46]
ADC Info	ADC1-1	Cofetuzumab	Inactive tyrosine-protein kinase 7 (PTK7)	ADC 1-1 payload	ADC 1-1 linker	[46]
ADC Info	ADC1-12	Cofetuzumab	Inactive tyrosine-protein kinase 7 (PTK7)	ADC 1-12 payload	ADC 1-12 linker	[46]
ADC Info	ADC2-A	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-A payload	ADC 2-A linker	[46]
ADC Info	ADC2-B	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-B payload	ADC 2-B linker	[46]
ADC Info	ADC2-12	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	ADC 2-12 payload	ADC 2-12 linker	[46]
ADC Info	ADC-C1	Patritumab	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	ADC-C1 payload	ADC-C1 linker	[46]
ADC Info	Sacituzumab-Deruxtecan	Sacituzumab	Tumor-associated calcium signal transducer 2 (TACSTD2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[47]
ADC Info	WO2022078260A1 ADC-1	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Ln-D9	WO2022078260A1_ADC-1 linker	[48]
ADC Info	WO2022078260A1 ADC-2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Ln-D1	WO2022078260A1_ADC-2 linker	[48]
ADC Info	WO2022078260A1 ADC-3	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Ln-D2	WO2022078260A1_ADC-3 linker	[48]
ADC Info	WO2022078260A1 ADC-4	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Ln-D4	WO2022078260A1_ADC-4 linker	[48]
ADC Info	WO2022078260A1 ADC-5	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Ln-D5	WO2022078260A1_ADC-5 linker	[48]
ADC Info	WO2022078260A1 ADC-6	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Ln-D6	WO2022078260A1_ADC-6 linker	[48]
ADC Info	WO2022078260A1 ADC-7	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Ln-D7	WO2022078260A1_ADC-7 linker	[48]
ADC Info	WO2022078260A1 ADC-8	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Ln-D8	WO2022078260A1_ADC-8 linker	[48]
ADC Info	WO2022078260A1 ADC-9	Cetuximab	Epidermal growth factor receptor (EGFR)	Ln-D2	WO2022078260A1_ADC-9 linker	[48]
ADC Info	WO2022078260A1 ADC-10	Cetuximab	Epidermal growth factor receptor (EGFR)	Ln-D7	WO2022078260A1_ADC-10 linker	[48]
ADC Info	Epratuzumab-CL2E-SN-38	Epratuzumab	B-cell receptor CD22 (CD22)	Active metabolite of irinotecan SN38	CL2E	[49]
ADC Info	Epratuzumab-SN-38	Epratuzumab	B-cell receptor CD22 (CD22)	Active metabolite of irinotecan SN38	CL2A	[49]
ADC Info	Veltuzumab-SN-38	Veltuzumab	B-lymphocyte antigen CD20 (MS4A1)	Active metabolite of irinotecan SN38	CL2A	[49]
ADC Info	Veltuzumab-CL2E-SN-38	Veltuzumab	B-lymphocyte antigen CD20 (MS4A1)	Active metabolite of irinotecan SN38	CL2E	[49]
ADC Info	Labetuzumab-CL2E-SN-38	Labetuzumab	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	Active metabolite of irinotecan SN38	CL2E	[49]
ADC Info	Labetuzumab-SN-38	Labetuzumab	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	Active metabolite of irinotecan SN38	CL2A	[49]
ADC Info	Sacituzumab-SN-38	Sacituzumab	Tumor-associated calcium signal transducer 2 (TACSTD2)	Active metabolite of irinotecan SN38	CL2A	[49]
ADC Info	IBI130	Anti-TROP2 antibody	TROP2	NT1	A cleavable linker	[50]

Investigative

Click To Hide/Show 516 ADC Related to This Stage

ADC Info	ADC Name	Antibody	Antigen	Payload	Linker	Ref
ADC Info	H01L02-Dxd	H01L02	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[51]
ADC Info	H02L02-Dxd	H02L02	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[51]
ADC Info	H02L03-Dxd	H02L03	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[51]
ADC Info	H04L02-Dxd	H04L02	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[51]
ADC Info	NOV0712-Dxd	NOV0712	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[51]
ADC Info	izalontamab brengitecan	Izalontamab	EGFR; HER3	Ed-04	Gly-Mal-Gly-Gly-Phe-Gly
ADC Info	CBX-12	Undisclosed	Undisclosed	Exatecan	Undisclosed	[52]
ADC Info	Epratuzumab-SN38	Epratuzumab	B-cell receptor CD22 (CD22)	Active metabolite of irinotecan SN38	CL2A	[53]
ADC Info	MGC026	Vobramitamab	B7-H3	Exatecan	Bicyclononyne carbamoyl sulfamide Val-Ala-PABC
ADC Info	MTX-13	Ab13	PTK7	Exatecan	T1000	[54]
ADC Info	T-Ed9	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Ed9	Mc-Gly-Gly-Phe-Gly	[55]
ADC Info	T-VEd9	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Ed9	Mc-Val-Ala	[55]
ADC Info	38139459 8D302-DXd	8D302	Sortilin (SORT1)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[56]
ADC Info	Control to 8D302-DXd	undisclosed	undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[56]
ADC Info	Control-DXd-DAR8	undisclosed	undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[57]
ADC Info	hu1084-DXd-DAR3	Hu1084	Undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[57]
ADC Info	hu1084-DXd-DAR8	Hu1084	Undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[57]
ADC Info	J87-Dxd	J87	T-cell antigen CD7 (CD7)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[58]
ADC Info	CD66c-DXd	undisclosed	Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[59]
ADC Info	bsSORT1×HER2-DXd	bsSORT1×HER2	Programmed cell death 1 ligand 1 (PD-L1)	DX-8951 derivative (DXd)	Undisclosed	[60]
ADC Info	bsSORT1×CTRL-DXd	bsSORT1×CTRL	Programmed cell death 1 ligand 1 (PD-L1)	DX-8951 derivative (DXd)	Undisclosed	[60]
ADC Info	bsCTRL×HER2-DXd	bsCTRL×HER2	Programmed cell death 1 ligand 1 (PD-L1)	DX-8951 derivative (DXd)	Undisclosed	[60]
ADC Info	Trastuzumab-DXd (38003245)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Undisclosed	[60]
ADC Info	38679234 ADC2	undisclosed	undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[61]
ADC Info	40285886 7300-Deruxtecan	7300	CD276 antigen (CD276)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[62]
ADC Info	39757732 ADC4	Ab-2	Undisclosed	DX-8951 derivative (DXd)	D4 Linker	[63]
ADC Info	40410803 16B10-Dxd	16B10	Transforming growth factor alpha (TGFA)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[64]
ADC Info	40410803 5F1-Dxd	5F1	Transforming growth factor alpha (TGFA)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[64]
ADC Info	39812376 84-Dxd	#84.7	Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6)	DX-8951 derivative (DXd)	Undisclosed	[65]
ADC Info	OncoFAP-GlyPro-Dxd	OncoFAP	Prolyl endopeptidase FAP (FAP)	DX-8951 derivative (DXd)	Maleimido Caproyl-GlyPro-PAB linker	[66]
ADC Info	ICAM-1-Dxd	undisclosed	Intercellular adhesion molecule 1 (ICAM-1)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[67]
ADC Info	37520726 I1-DXd	undisclosed	Intercellular adhesion molecule-1 (ICAM1)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[68]
ADC Info	OBI-902	Anti-TROP2 mAb	TROP2	Exatecan	A cleavable linker	[69]
ADC Info	MNC2-deruxtecan	huMNC2	Mucin-1 (MUC1)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[70]
ADC Info	Non-pH-B7-H3 Ab-Dxd	Non-pH-B7-H3 Ab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[71]
ADC Info	pH-B7-H3 Ab-Dxd	pH-B7-H3 Ab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[71]
ADC Info	TJ101	Anti-B7H3/EGFR bsAb	B7-H3; EGFR	PY-4car2	A cleavable linker	[72]
ADC Info	ZL-6201	Anti-LRRC15 antibody	LRRC15	YL0010014	VK*G-NHCH2-O linker	[73]
ADC Info	MHB042C	Anti-c-Met antibody	c-Met	MH30010008	Undisclosed	[74]
ADC Info	LM-350	LM-150	CDH17	LDX2	A cleavable linker	[75]
ADC Info	DB-1418	Anti-EGFR/HER3 bsAb	EGFR; HER3	P1021	Mc-Gly-Gly-Phe-Gly	[76]
ADC Info	AZD0516	Anti-STEAP2 mAb	STEAP2	Exatecan	A cleavable linker	[77]
ADC Info	BG-C137	Anti-FGFR2 antibody	FGFR2	TOP1 inhibitor	A cleavable linker	[78]
ADC Info	AMT-754	Ab-754	tissue factor	Exatecan	T1000	[79]
ADC Info	MHB009C	Anti-B7H4 antibody	B7-H4	MH30010008	Undisclosed	[80]
ADC Info	TD001	HuJ591	PSMA	Exatecan	A cleavable linker	[81]
ADC Info	LBL-054-Dxd	humanized CDH17 IgG1 monoclonal antibody	Cadherin-17 (CDH17)	DX-8951 derivative (DXd)	Undisclosed	[82]
ADC Info	YL242	Anti-VEGF antibody	VEGF	YL0010014	VK*G-NHCH2-O linker	[83]
ADC Info	BGB-C354	Anti-B7H3 antibody	B7-H3	TOP1 inhibitor	A cleavable linker	[84]
ADC Info	ADCE-017	undisclosed	urokinase plasminogen activator receptor-associated protein (uPARAP)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[85]
ADC Info	ADCE-202	undisclosed	urokinase plasminogen activator receptor-associated protein (uPARAP)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[85]
ADC Info	MHB048C	Anti-PSMA antibody	PSMA	MH30010008	Undisclosed	[86]
ADC Info	JSKN022	Anti-αvβ6/PDL1 bsAb	αvβ6; PDL1	Alphatecan (T01)	A cleavable linker	[87]
ADC Info	SYS6041	Anti-FRα mAb	FRα	Exatecan	A cleavable linker	[88]
ADC Info	PF-08046876	Sigvotatug	ITGB6	AMDCPT	Mal based β-glucuronide linker	[89]
ADC Info	HDM2017	Anti-CDH17 antibody	CDH17	CPT-derivative payloads	Undisclosed	[90]
ADC Info	BG-C477	Anti-CEA antibody	CEA	TOP1 inhibitor	A cleavable linker	[91]
ADC Info	ABBV-291	Anti-CD79b antibody	CD79b	TOP1 inhibitor	Undisclosed	[92]
ADC Info	ACR246	Anti-5T4 humanized mAb	5T4	D-2102	A cleavable linker	[93]
ADC Info	Trastuzumab-Example 6	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	CN119343152A Trastuzumab-Example6 Payload	CN119343152A 1C1-Example1 Linker	[94]
ADC Info	Trastuzumab-Example 7	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	CN119343152A Trastuzumab-Example6 Payload	CN119343152A Trastuzumab-Example7 Linker	[94]
ADC Info	Trastuzumab-Example 8	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119343152A Trastuzumab-Example8 Linker	[94]
ADC Info	Trastuzumab-GDP-D-P2/P4-P4-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119343152A Trastuzumab-GDP-D-P2/P4-P4-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-K-P2/P4-P4-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P2/P4-P4-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-D-P2/P8-P4-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P2/P8-P4-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-D-P1/P2-P4-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P2/P4-P4-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-D-P1/P1-P4-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P1/P1-P4-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-D-P2/P4-P1-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P2/P4-P1-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-D-P2/P4-P2-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P2/P4-P2-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-D-P1/P1-P1-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P1/P1-P1-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-D-P1/P1-P2-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P1/P1-P2-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-D-P1/P1-C2-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P1/P1-C2-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-D-P1/P2-C2-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P1/P2-C2-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-D-P1/P2-P1-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P1/P2-P1-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-N-P1/P2-P1-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-N-P1/P2-P1-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-N-P1/P1-P1-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-N-P1/P1-P1-GGFG-Dxd Linker	[95]
ADC Info	Trastuzumab-GDP-D-P2/P2-P2-GGFG-Dxd	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Trastuzumab-GDP-D-P2/P2-P2-GGFG-Dxd Linker	[95]
ADC Info	Rituximab-GDP-D-P1/P1-P1-GGFG-Dxd	Rituximab	B-lymphocyte antigen CD20 (MS4A1)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P1/P1-P1-GGFG-Dxd Linker	[95]
ADC Info	Rituximab-GDP-D-P2/P8-P4-GGFG-Dxd	Rituximab	B-lymphocyte antigen CD20 (MS4A1)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P2/P8-P4-GGFG-Dxd Linker	[95]
ADC Info	Rituximab-GDP-D-P2/P4-P4-GGFG-Dxd	Rituximab	B-lymphocyte antigen CD20 (MS4A1)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P2/P4-P4-GGFG-Dxd Linker	[95]
ADC Info	Rituximab-GDP-D-P1/P1-P4-GGFG-Dxd	Rituximab	B-lymphocyte antigen CD20 (MS4A1)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P1/P1-P4-GGFG-Dxd Linker	[95]
ADC Info	Rituximab-GDP-D-P1/P1-P2-GGFG-Dxd	Rituximab	B-lymphocyte antigen CD20 (MS4A1)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P1/P1-P2-GGFG-Dxd Linker	[95]
ADC Info	Rituximab-GDP-D-P1/P1-C2-GGFG-Dxd	Rituximab	B-lymphocyte antigen CD20 (MS4A1)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-D-P1/P1-C2-GGFG-Dxd Linker	[95]
ADC Info	Rituximab-GDP-D-P2/P2-P2-GGFG-Dxd	Rituximab	B-lymphocyte antigen CD20 (MS4A1)	DX-8951 derivative (DXd)	Trastuzumab-GDP-D-P2/P2-P2-GGFG-Dxd Linker	[95]
ADC Info	Rituximab-GDP-N-P1/P1-P1-GGFG-Dxd	Rituximab	B-lymphocyte antigen CD20 (MS4A1)	DX-8951 derivative (DXd)	CN119326907A Trastuzumab-GDP-N-P1/P1-P1-GGFG-Dxd Linker	[95]
ADC Info	Rituximab-GDP-K-P2/P4-P4-GGFG-Dxd	Rituximab	B-lymphocyte antigen CD20 (MS4A1)	DX-8951 derivative (DXd)	Trastuzumab-GDP-D-P2/P2-P2-GGFG-Dxd Linker	[95]
ADC Info	aHer2- (AL6-LP1)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP1)n Linker	[96]
ADC Info	aHer2- (AL6-LP15)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP15)n Linker	[96]
ADC Info	aHer2- (AL6-LP13)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP13)n Linker	[96]
ADC Info	aHer2- (AL7-LP1)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP1)n Linker	[96]
ADC Info	FeID1- (AL7-LP1)n	FeID1	DNA-binding protein inhibitor ID-1 (ID1)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP1)n Linker	[96]
ADC Info	aHer2- (AL7-LP13)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP13)n Linker	[96]
ADC Info	FeID1- (AL7-LP13)n	FeID1	DNA-binding protein inhibitor ID-1 (ID1)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP13)n Linker	[96]
ADC Info	aHer2- (AL7-LP5)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	CP1436	US20240269308A1 aHer2- (AL7-LP5)n Linker	[96]
ADC Info	FeID1- (AL7-LP5)n	FeID1	DNA-binding protein inhibitor ID-1 (ID1)	CP1436	US20240269308A1 aHer2- (AL7-LP5)n Linker	[96]
ADC Info	aHer2- (AL7-LP12)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	CP1436	US20240269308A1 aHer2- (AL7-LP5)n Linker	[96]
ADC Info	FeID1- (AL7-LP12)n	FeID1	DNA-binding protein inhibitor ID-1 (ID1)	CP1436	US20240269308A1 aHer2- (AL7-LP5)n Linker	[96]
ADC Info	aHer2- (AL7-LP5D)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	CP1436	US20240269308A1 aHer2- (AL7-LP5D)n Linker	[96]
ADC Info	FeID1- (AL7-LP5D)n	FeID1	DNA-binding protein inhibitor ID-1 (ID1)	CP1436	US20240269308A1 aHer2- (AL7-LP5D)n Linker	[96]
ADC Info	aHer2- (AL4c-LP1B)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL4c-LP1B)n Linker	[96]
ADC Info	FeID1- (AL4c-LP1B)n	FeID1	DNA-binding protein inhibitor ID-1 (ID1)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL4c-LP1B)n Linker	[96]
ADC Info	aHer2- (AL4c-LP13C)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL4c-LP13C)n Linker	[96]
ADC Info	FeID1- (AL4c-LP13C)n	FeID1	DNA-binding protein inhibitor ID-1 (ID1)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL4c-LP13C)n Linker	[96]
ADC Info	aHer2- (AL11a-LP1)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP1)n Linker	[96]
ADC Info	FeID1- (AL11a-LP1)n	FeID1	DNA-binding protein inhibitor ID-1 (ID1)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP1)n Linker	[96]
ADC Info	aHer2- (AL11a-LP13)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP13)n Linker	[96]
ADC Info	FeID1- (AL11a-LP13)n	FeID1	DNA-binding protein inhibitor ID-1 (ID1)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP13)n Linker	[96]
ADC Info	aHer2- (AL11a-LP15)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP15)n Linker	[96]
ADC Info	FeID1- (AL11a-LP15)n	FeID1	DNA-binding protein inhibitor ID-1 (ID1)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP15)n Linker	[96]
ADC Info	aHer2- (BL1-LP1)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP1)n Linker	[96]
ADC Info	FeID1- (BL1-LP1)n	FeID1	DNA-binding protein inhibitor ID-1 (ID1)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP1)n Linker	[96]
ADC Info	aHer2- (BL1-LP13)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP13)n Linker	[96]
ADC Info	FeID1- (BL1-LP13)n	FeID1	DNA-binding protein inhibitor ID-1 (ID1)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP13)n Linker	[96]
ADC Info	aHer2- (BL3b-LP1)n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP1)n Linker	[96]
ADC Info	FeID1- (BL3b-LP1)n	FeID1	DNA-binding protein inhibitor ID-1 (ID1)	DX-8951 derivative (DXd)	US20240269308A1 aHer2- (AL6-LP1)n Linker	[96]
ADC Info	LN488-01-2	BY016	Tumor-associated calcium signal transducer 2 (TACSTD2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[97]
ADC Info	CN117616052A Antibody A-ADC1	Antibody A	Receptor tyrosine-protein kinase erbB-3 (ERBB3)	DX-8951 derivative (DXd)	DBCO-PEG4-GGFG-aminol	[98]
ADC Info	CN115969996A ADC2	Antibody V3	CD276 antigen (CD276)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[99]
ADC Info	AU2023226367A1-2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	U-030	RU20241285-1-linker	[100]
ADC Info	AU2023226367A1-11	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	RU20241285-10-linker	[100]
ADC Info	AU2023226367A1-12	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	RU20241285-12-linker	[100]
ADC Info	AU2023226367A1-13	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	RU20241285-13-linker	[100]
ADC Info	AU2023226367A1-20	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Topo1 inhibitor A	EP4487874A1-13linker	[100]
ADC Info	AU2023226367A1-23	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	RU20241285-23-payload	RU20241285-23-linker	[100]
ADC Info	AU2023226367A1-24	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	RU20241285-23-payload	RU20241285-24-linker	[100]
ADC Info	ZA202500202A 2188-D04-Y180/F404-LP10	2188-D04-Y180/F404	Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)	DX-8951 derivative (DXd)	DBCO-PEG4-GGFG-aminol	[101]
ADC Info	ZA202500202A 2188-D04-Y180/F404/K42/E161-LP10	2188-D04-Y180/F404/K42/E161	Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)	DX-8951 derivative (DXd)	DBCO-PEG4-GGFG-aminol	[101]
ADC Info	FS001-VH3-VL2-Dxd	FS001-huVH3-huVL2	Glypican-3 (GPC3)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[102]
ADC Info	FS001-VH4-VL3-Dxd	FS001-huVH4-huVL3	Glypican-3 (GPC3)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[102]
ADC Info	WO2024193682A1 32G1-8D9-CPT2	undisclosed	Trophoblast glycoprotein (TPBG)	CPT2	Undisclosed	[103]
ADC Info	WO2024193682A1 32G1-8H10-CPT2	undisclosed	Trophoblast glycoprotein (TPBG)	CPT2	Undisclosed	[103]
ADC Info	WO2024193682A1 32G1-2F11-CPT2	undisclosed	Trophoblast glycoprotein (TPBG)	CPT2	Undisclosed	[103]
ADC Info	PF06263507-CPT2	undisclosed	Trophoblast glycoprotein (TPBG)	CPT2	Undisclosed	[103]
ADC Info	SYD-1875-CPT2	undisclosed	Trophoblast glycoprotein (TPBG)	CPT2	Undisclosed	[103]
ADC Info	Telisotuzumab-CPT2	undisclosed	Trophoblast glycoprotein (TPBG)	CPT2	Undisclosed	[103]
ADC Info	WO2024193682A1 32G1-CPT2	undisclosed	Trophoblast glycoprotein (TPBG)	CPT2	Undisclosed	[103]
ADC Info	WO2024193682A1 2F11-CPT2	undisclosed	Trophoblast glycoprotein (TPBG)	CPT2	Undisclosed	[103]
ADC Info	WO2024092067A1 2E7-deruxtecan	20000000	CD70 antigen (CD70)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[104]
ADC Info	Ab[AL- LP9]	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Undisclosed	[105]
ADC Info	Ab[AL2- LP17]n	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Undisclosed	[105]
ADC Info	Ab[AL2- LP17]	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Undisclosed	[105]
ADC Info	KR1020250012631A+ADC	undisclosed	Cadherin-6 (CDH6)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[106]
ADC Info	IN202417103159A 2188-IN202417103159A D04-Yl80/F404-LP10	undisclosed	Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)	DX-8951 derivative (DXd)	DBCO-PEG4-GGFG-aminol	[107]
ADC Info	IN202417103159A 2188-IN202417103159A D04-Yl80/F404/K42/E161 LP10	undisclosed	Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)	DX-8951 derivative (DXd)	DBCO-PEG4-GGFG-aminol	[107]
ADC Info	Tra-25-4	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	PBX-7014	Mc-Gly-Gly-Phe-Gly	[108]
ADC Info	Tra-25-6	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	PBX-7016	Mc-Gly-Gly-Phe-Gly	[108]
ADC Info	WBP301088-X2	Anti-b7h3	CD276 antigen (CD276)	Topo1 inhibitor F	Mc-Gly-Gly-Phe-Gly	[109]
ADC Info	SG11202408662TA ADC-C1	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[110]
ADC Info	HER2-Dxd	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Undisclosed	[111]
ADC Info	IN202417078684A+ADC7	IN202417078684A+Ab4	Undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[112]
ADC Info	IN202417078684A+ADC8	IN202417078684A+Ab4	Undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[112]
ADC Info	US20240245795A1 Antibody Conjugate 7	trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Antibody Conjugate 7 +Payload	Undisclosed	[113]
ADC Info	US20240245795A1 Antibody Conjugate 15	hRS7	Tumor-associated calcium signal transducer 2 (TACSTD2)	Antibody Conjugate 7 +Payload	Undisclosed	[113]
ADC Info	CN112341521B+ADC-5	Nimotuzumab	V-set domain-containing T-cell activation inhibitor 1 (VTCN1)	Topo1 inhibitor D	CN112341521B+Linker3	[114]
ADC Info	CN112341521B+ADC-6	Nimotuzumab	V-set domain-containing T-cell activation inhibitor 1 (VTCN1)	Topo1 inhibitor D	Undisclosed	[114]
ADC Info	CN112341521B+ADC-7	Nimotuzumab	V-set domain-containing T-cell activation inhibitor 1 (VTCN1)	Topo1 inhibitor D	Undisclosed	[114]
ADC Info	CN112341521B+ADC-11	Nimotuzumab	V-set domain-containing T-cell activation inhibitor 1 (VTCN1)	CN112341521B+Payload11	CN112341521B+Linker11	[114]
ADC Info	CN112341521B+ADC-12	Nimotuzumab	V-set domain-containing T-cell activation inhibitor 1 (VTCN1)	CN112341521B+Payload11	CN112341521B+Linker12	[114]
ADC Info	EP4494658A1 antibody-drug conjugate 1	900698	Thymidylate 5'-phosphatase (NT5E)	EP4494658A1 antibody-drug conjugate 1 payload	EP4494658A1 antibody-drug conjugate 1	[115]
ADC Info	EP4494658A1 antibody-drug conjugate 2	900698	Thymidylate 5'-phosphatase (NT5E)	EP4494658A1 antibody-drug conjugate 1 payload	EP4494658A1 antibody-drug conjugate 2	[115]
ADC Info	PnakoMab-ADC	PankoMab	Mucin-1 (MUC1)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[116]
ADC Info	PM-N54Q-ADC	PM-N54Q	Mucin-1 (MUC1)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[116]
ADC Info	EP4471061A1 17c10_MC-Dxd	huASCT2 17c10 mAb	Amino acid transporter (ASCT2)	DX-8951 derivative (DXd)	6-Maleimidocaproic acid	[117]
ADC Info	ICT_MC-Dxd (Isotype control)	huASCT2 17c10 mAb	Amino acid transporter (ASCT2)	DX-8951 derivative (DXd)	6-Maleimidocaproic acid	[117]
ADC Info	EP4471061A1 MC_Dxd	huASCT2 17c10 mAb	Amino acid transporter (ASCT2)	DX-8951 derivative (DXd)	6-Maleimidocaproic acid	[117]
ADC Info	WO2024110905A1 ADC2-27	undisclosed	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	DX-8951 derivative (DXd)	Linker of ADC2-27	[118]
ADC Info	WO2024110905A1 ADC2-38	undisclosed	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	DX-8951 derivative (DXd)	Linker of ADC2-38	[118]
ADC Info	WO2024110905A1 ADC2-49	undisclosed	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	DX-8951 derivative (DXd)	Linker of ADC2-49	[118]
ADC Info	WO2024110905A1 ADC2-58	undisclosed	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	DX-8951 derivative (DXd)	Linker of ADC2-58	[118]
ADC Info	WO2024110905A1 ADC2-61	undisclosed	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	DX-8951 derivative (DXd)	Linker of ADC2-61	[118]
ADC Info	WO2024110905A1 ADC3-7	undisclosed	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	DX-8951 derivative (DXd)	Linker of ADC2-49	[118]
ADC Info	WO2024110905A1 ADC3-12	undisclosed	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	DX-8951 derivative (DXd)	Linker of ADC2-58	[118]
ADC Info	WO2024110905A1 ADC3-15	undisclosed	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	DX-8951 derivative (DXd)	Linker of ADC2-61	[118]
ADC Info	WO2024110905A1 ADC3-16	undisclosed	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	DX-8951 derivative (DXd)	Linker of ADC3-16	[118]
ADC Info	WO2024110905A1 ADC3-17	undisclosed	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	DX-8951 derivative (DXd)	Linker of ADC3-16	[118]
ADC Info	WO2024110905A1 ADC3-18	undisclosed	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	DX-8951 derivative (DXd)	Mc-Val-Ala	[118]
ADC Info	WO2024110905A1 ADC-1 BGB-C-81	undisclosed	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[118]
ADC Info	BGA2588	BGA5384	Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[118]
ADC Info	aHer2- (AL6-LP13D)_6.2	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	aHer2- (AL6-LP13D)<sub>6.2</sub> Linker	[119]
ADC Info	aHer2- (AL7-LP3)_3.88	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	aHer2- (AL7-LP2)<sub>3.83</sub> Linker	[119]
ADC Info	FelD1- (AL7-LP3)_3.82	undisclosed	Undisclosed	DX-8951 derivative (DXd)	aHer2- (AL7-LP2)<sub>3.83</sub> Linker	[119]
ADC Info	aHer2- (AL7-LP4)_3.84	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	aHer2- (AL7-LP2)<sub>3.83</sub> Linker	[119]
ADC Info	FelD1- (AL7-LP4)_3.82	undisclosed	Undisclosed	DX-8951 derivative (DXd)	aHer2- (AL7-LP2)<sub>3.83</sub> Linker	[119]
ADC Info	aHer2- (AL11a-LP15)_7.6	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	aHer2- (AL11a-LP15)<sub>7.6</sub> Linker	[119]
ADC Info	FelD1- (AL11a-LP15)_7.0	undisclosed	Undisclosed	DX-8951 derivative (DXd)	aHer2- (AL11a-LP15)<sub>7.6</sub> Linker	[119]
ADC Info	aHer2 1- (Mc-GGFG-DXD)_7.7	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[119]
ADC Info	aHer2 2- (Mc-GGFG-DXD)_7.7	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[119]
ADC Info	aHer2 3- (Mc-GGFG-DXD)_7.7	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[119]
ADC Info	FelD1 1- (Mc-GGFG-DXD)_7.5	undisclosed	Undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[119]
ADC Info	FelD1 2- (Mc-GGFG-DXD)_7.5	undisclosed	Undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[119]
ADC Info	FelD1 3- (Mc-GGFG-DXD)_7.5	undisclosed	Undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[119]
ADC Info	aHer2 1- (Mc-GGFG-DXD)_7.1	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[119]
ADC Info	aHer2 2- (Mc-GGFG-DXD)_7.1	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[119]
ADC Info	aHer2 3- (Mc-GGFG-DXD)_7.1	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[119]
ADC Info	FelD1 1- (Mc-GGFG-DXD)_7.0	undisclosed	Undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[119]
ADC Info	FelD1 2- (Mc-GGFG-DXD)_7.0	undisclosed	Undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[119]
ADC Info	FelD1 3- (Mc-GGFG-DXD)_7.0	undisclosed	Undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[119]
ADC Info	WO2024105206A1 16i-5657 2	TPP-5657	Undisclosed	Mdo-cpt	16i-5657 Linker	[120]
ADC Info	WO2024105206A1 19i-5657 2	TPP-5657	Undisclosed	Mdo-cpt	6i-5657 Linker	[120]
ADC Info	WO2024105206A1 23i-5657 2	TPP-5657	Undisclosed	Mdo-cpt	23i-5657 Linker	[120]
ADC Info	WO2024105206A1 23p-Avelu 2	Avelumab	Programmed cell death 1 ligand 1 (PD-L1)	Mdo-cpt	23i-5657 Linker	[120]
ADC Info	WO2024105206A1 27i-5657 2	TPP-5657	Undisclosed	Mdo-cpt	22i-5657 Linker	[120]
ADC Info	WO2024105206A1 28i-5657 2	TPP-5657	Undisclosed	Mdo-cpt	6i-5657 Linker	[120]
ADC Info	WO2024105206A1 29p-Avelu 2	TPP-Avelumab	Programmed cell death 1 ligand 1 (PD-L1)	Mdo-cpt	29p-Avelu Linker	[120]
ADC Info	WO2024105206A1 32p-Avelu 2	TPP-Avelumab	Programmed cell death 1 ligand 1 (PD-L1)	Mdo-cpt	32p-Avelu Linker	[120]
ADC Info	WO2024105206A1 32e-1015 2	TPP-1015	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Mdo-cpt	32p-Avelu Linker	[120]
ADC Info	AU2017341000B2 ADC (1)	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[121]
ADC Info	H01L02-ADC	Anti-CDH6 mAb H01L02	Cadherin-6 (CDH6)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[122]
ADC Info	WO2024231224A2 ADC-AFI-DXd	mAb_v64	Tumor-associated carbohydrate antigen sialyl-Tn (STn)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[123]
ADC Info	HK40112172A Antibody-drug conjugate (5)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	HK40112172A+Antibody-drug conjugate (4)+Linker	[124]
ADC Info	HK40112172A Antibody-drug conjugate (6)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	HK40112172A+Antibody-drug conjugate (6)+Linker	[124]
ADC Info	HK40112172A Antibody-drug conjugate (7)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	HK40112172A+Antibody-drug conjugate (7)+Linker	[124]
ADC Info	HK40112172A Antibody-drug conjugate (8)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	HK40112172A+Antibody-drug conjugate (7)+Linker	[124]
ADC Info	HK40112172A Antibody-drug conjugate (9)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	HK40112172A+Antibody-drug conjugate (7)+Linker	[124]
ADC Info	HK40112172A Antibody-drug conjugate (10)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	HK40112172A+Antibody-drug conjugate (7)+Linker	[124]
ADC Info	HK40112172A Antibody-drug conjugate (12)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC13 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (13)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC13 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (15)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC13 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (16)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC13 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (21)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	HK40112172A+Antibody-drug conjugate (7)+Linker	[124]
ADC Info	HK40112172A Antibody-drug conjugate (22)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	HK40112172A+Antibody-drug conjugate (7)+Linker	[124]
ADC Info	HK40112172A Antibody-drug conjugate (24)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC25 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (25)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC25 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (26)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (27)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (28)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (29)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (30)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (31)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (36)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	SCHEMBL17022441	[124]
ADC Info	HK40112172A Antibody-drug conjugate (37)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC37 payload	SCHEMBL17022441	[124]
ADC Info	HK40112172A Antibody-drug conjugate (41)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Topo1 inhibitor B	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (42)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Topo1 inhibitor B	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (43)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	HK40112172A+Antibody-drug conjugate (43)+Linker	[124]
ADC Info	HK40112172A Antibody-drug conjugate (44)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	HK40112172A+Antibody-drug conjugate (44)+Linker	[124]
ADC Info	HK40112172A Antibody-drug conjugate (46)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (47)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (48)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	HK40112172A Antibody-drug conjugate (49)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[124]
ADC Info	mAb1-DXd	mAb1	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[125]
ADC Info	mAb2-DXd	Undisclosed	Undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[125]
ADC Info	mAb3-DXd	Undisclosed	Undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[125]
ADC Info	mAb17-DXd	Undisclosed	Undisclosed	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[125]
ADC Info	cD44-DRT	Undisclosed	CD44 antigen (CD44)	DX-8951 derivative (DXd)	CN117362435A+CD44-DRT+Linker	[126]
ADC Info	isumab01-C4	Undisclosed	Folate receptor alpha (FRalpha)	compound 4	Undisclosed	[127]
ADC Info	isumab01-C5	Undisclosed	Folate receptor alpha (FRalpha)	compound 5	Undisclosed	[127]
ADC Info	isumab04-C5	Undisclosed	Undisclosed	compound 5	Undisclosed	[127]
ADC Info	wO2024140449A1 ADC5	HS627	Undisclosed	WO2024140449A1+ADC5+payload	WO2024140449A1+ADC5+Linker	[128]
ADC Info	wO2024140449A1 ADC6	IP140B	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	WO2024140449A1+ADC5+payload	WO2024140449A1+ADC5+Linker	[128]
ADC Info	wO2024140449A1 ADC7	HS627	Undisclosed	WO2024140449A1+ADC5+payload	WO2024140449A1+ADC7+Linker	[128]
ADC Info	wO2024140449A1 ADC8	IP140B	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	WO2024140449A1+ADC5+payload	WO2024140449A1+ADC7+Linker	[128]
ADC Info	wO2024140449A1 ADC9	HS627	Undisclosed	WO2024140449A1+ADC5+payload	WO2024140449A1+ADC9+Linker	[128]
ADC Info	wO2024140449A1 ADC10	IP140B	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	WO2024140449A1+ADC5+payload	WO2024140449A1+ADC9+Linker	[128]
ADC Info	wO2024140449A1 ADC11	HS627	Undisclosed	WO2024140449A1+ADC5+payload	WO2024140449A1+ADC9+Linker	[128]
ADC Info	wO2024140449A1 ADC12	IP140B	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	WO2024140449A1+ADC5+payload	WO2024140449A1+ADC9+Linker	[128]
ADC Info	wO2024140449A1 ADC21	HS627	Undisclosed	WO2024140449A1+ADC5+payload	WO2024140449A1+ADC5+Linker	[128]
ADC Info	wO2024140449A1 ADC22	IP140B	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	WO2024140449A1+ADC5+payload	WO2024140449A1+ADC5+Linker	[128]
ADC Info	diS-Compound -145	Undisclosed	Undisclosed	FD6	TW202426058A+DiS-Compound -145+Linker	[129]
ADC Info	mT-GGFG-Compound140	undisclosed	undisclosed	10NH2-11F-Camptothecin	CN115160403A+B17+Linker	[129]
ADC Info	mT-GGFG-Compound141	undisclosed	undisclosed	FD5	CN115160403A+B17+Linker	[129]
ADC Info	mT-GGFG-Compound145	undisclosed	undisclosed	FD5	CN115160403A+B17+Linker	[129]
ADC Info	mT-GGFG-Compound148	undisclosed	undisclosed	FD7	CN115160403A+B17+Linker	[129]
ADC Info	nHC-C-VA-Compound140	Undisclosed	Undisclosed	10NH2-11F-Camptothecin	TW202426058A+NHC-C--VA-Compound140+Linker	[129]
ADC Info	cN115160403A B1	Undisclosed	Undisclosed	CN115160403A+B1+payload	Mc-Gly-Gly-Phe-Gly	[130]
ADC Info	cN115160403A B7	Undisclosed	Undisclosed	CN115160403A+B7+payload	Mc-Gly-Gly-Phe-Gly	[130]
ADC Info	cN115160403A B13	Undisclosed	Undisclosed	(4-NH2)-Exatecan	CN115160403A+B11+Linker	[130]
ADC Info	cN115160403A B14	Undisclosed	Undisclosed	CN115160403A+B1+payload	CN115160403A+B14+Linker	[130]
ADC Info	cN115160403A B15	Undisclosed	Undisclosed	CN115160403A+B1+payload	CN115160403A+B15+Linker	[130]
ADC Info	cN115160403A B16	Undisclosed	Undisclosed	CN115160403A+B7+payload	CN115160403A+B11+Linker	[130]
ADC Info	cN115160403A B17	Undisclosed	Undisclosed	CN115160403A+B7+payload	CN115160403A+B17+Linker	[130]
ADC Info	cN115160403A B18	Undisclosed	Undisclosed	CN115160403A+B7+payload	CN115160403A+B18+Linker	[130]
ADC Info	cN119072334A Formula 8	undisclosed	Undisclosed	Topo1 inhibitor H	CN119072334A+Formula 8+Linker	[131]
ADC Info	thioBridge-Glu-[ (Val-Cit-PAB-MMáE)]2-Glu-[PEG (24u)]2	undisclosed	Undisclosed	Topo1 inhibitor H	CN119072334A+ThioBridge⑪-Glu-[ (Val-Cit-PAB-MMáE)]2-Glu-[PEG (24u)]2+Linker	[131]
ADC Info	aB1380049-SG3932 (DAR8)	AB1380049	Folate receptor alpha (FOLR1)	(4-NH2)-Exatecan	SG3932 Linker	[132]
ADC Info	aB1380026-SG3932	AB1380026	Folate receptor alpha (FOLR1)	(4-NH2)-Exatecan	SG3932 Linker	[132]
ADC Info	aB1380035-SG3932	AB1380035	Folate receptor alpha (FOLR1)	(4-NH2)-Exatecan	SG3932 Linker	[132]
ADC Info	aB1380083-SG3932	AB1380083	Folate receptor alpha (FOLR1)	(4-NH2)-Exatecan	SG3932 Linker	[132]
ADC Info	aB1380095-SG3932	AB1380095	Folate receptor alpha (FOLR1)	(4-NH2)-Exatecan	SG3932 Linker	[132]
ADC Info	aB1380117-SG3932	AB1380117	Folate receptor alpha (FOLR1)	(4-NH2)-Exatecan	SG3932 Linker	[132]
ADC Info	aB1380049-SG3932 (DAR4)	AB1380049	Folate receptor alpha (FOLR1)	(4-NH2)-Exatecan	SG3932 Linker	[132]
ADC Info	cN119317630A ADC-C1	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[133]
ADC Info	cN119317630A ADC-C2	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[133]
ADC Info	cN119317630A ADC-C3	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	CN119317630A ADC-C3 Linker	[133]
ADC Info	cN119317630A ADC-C4	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	CN119317630A ADC-C3 Linker	[133]
ADC Info	cN119317630A ADC-C5	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	CN119317630A ADC-C5 Linker	[133]
ADC Info	cN119317630A ADC-C6	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	CN119317630A ADC-C5 Linker	[133]
ADC Info	cN119317630A ADC-C7	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	CN119317630A ADC-C7 Linker	[133]
ADC Info	cN119317630A ADC-C8	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	CN119317630A ADC-C8 Linker	[133]
ADC Info	cN119317630A ADC-C9	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	CN119317630A ADC-C9 Linker	[133]
ADC Info	cN119317630A ADC-C10	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	CN119317630A ADC-C10 Linker	[133]
ADC Info	cN119317630A ADC-C11	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	CN119317630A ADC-C11 Linker	[133]
ADC Info	cN119317630A ADC-C12	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	CN119317630A ADC-C12 Linker	[133]
ADC Info	cN119317630A ADC-C13	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	CN119317630A ADC-C13 Linker	[133]
ADC Info	cN119317630A ADC-C14	Ifinatamab	CD276 antigen (CD276)	DX-8951 derivative (DXd)	CN119317630A ADC-C14 Linker	[133]
ADC Info	jP2024533562A ADC-4	undisclosed	Undisclosed	EP4494658A1 antibody-drug conjugate 1 payload	Mc-Val-Cit-PABC	[134]
ADC Info	jP2024533562A ADC-12	undisclosed	Undisclosed	EP4494658A1 antibody-drug conjugate 1 payload	JP2024533562A ADC-16 linker	[134]
ADC Info	sG11202200215QA ADC5	undisclosed	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	SG11202200215QA ADC5 linker	[135]
ADC Info	wO2023232144A1ADC-2	anti-HER2 antibody mAb-1	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	WO2023232144A1, ADC-2, Payload	WO2023232144A1, ADC-2, linker	[136]
ADC Info	wO2023232144A1ADC-3	anti-TROP2 antibody mAb-2	Tumor-associated calcium signal transducer 2 (TACSTD2)	WO2023232144A1, ADC-2, Payload	WO2023232144A1, ADC-2, linker	[136]
ADC Info	wO2023232144A1ADC-6	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	WO2023232144A1, ADC-2, Payload	WO2023232144A1, ADC-2, linker	[136]
ADC Info	wO2023232144A1ADC22	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	WO2025015586A1, ADC22, Payload	Mc-Val-Cit-PABC	[137]
ADC Info	wO2023232144A1ADC26	Avelumab	Programmed cell death 1 ligand 1 (CD274)	WO2025015586A1, ADC22, Payload	Mc-Val-Cit-PABC	[137]
ADC Info	wO2023232144A1ADC32	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	WO2025015586A1, ADC22, Payload	SMCC	[137]
ADC Info	wO2023232144A1ADC33	Avelumab	Programmed cell death 1 ligand 1 (CD274)	WO2025015586A1, ADC22, Payload	SMCC	[137]
ADC Info	dS-1062	anti-TROP2 antibody	Tumor-associated calcium signal transducer 2 (TACSTD2)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[138]
ADC Info	wO2025019776A2ADC 22-8	A22	Interleukin-13 receptor subunit alpha-2 (IL13RA2)	Belotecan	WO2025019776A2, ADC 22-8, Linker	[139]
ADC Info	wO2025019776A2ADC 33-8	A33	Interleukin-13 receptor subunit alpha-2 (IL13RA2)	Belotecan	WO2025019776A2, ADC 22-8, Linker	[139]
ADC Info	wO2025019776A2ADC 52-8	A52	Interleukin-13 receptor subunit alpha-2 (IL13RA2)	Belotecan	WO2025019776A2, ADC 22-8, Linker	[139]
ADC Info	wO2025019776A2ADC-00	P0	Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1); Tyrosine-protein kinase transmembrane receptor ROR2 (ROR2)	Belotecan	Undisclosed	[140]
ADC Info	wO2025019776A2ADC-11	M1	Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1); Tyrosine-protein kinase transmembrane receptor ROR2 (ROR2)	Belotecan	Undisclosed	[140]
ADC Info	wO2025019776A2ADC-13	M2	Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1); Tyrosine-protein kinase transmembrane receptor ROR2 (ROR2)	Belotecan	Undisclosed	[140]
ADC Info	wO2025019776A2ADC-M3	M3	Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1); Tyrosine-protein kinase transmembrane receptor ROR2 (ROR2)	Belotecan	Undisclosed	[140]
ADC Info	aU2023308528A1 ADC5	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	4- ((S)-2- ((S)-2-amino-3-methylbutanamido)propanamido)benzyl ((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)carbamate	Mal-amido-PEG8-acid	[141]
ADC Info	aU2023308528A1 ADC1	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	PBD aromatic-amide derivative	6-Maleimidocaproic acid	[141]
ADC Info	aU2023308528A1 ADC2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	PBD-butanamide derivative	6-Maleimidocaproic acid	[141]
ADC Info	aU2023308528A1 ADC7	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	N- (4- ((S)-2- ((S)-2-amino-3- methylbutanamido)propanamido)phenyl)-4- (4- (4- (4- (( (S)-2-methoxy-12-oxo-6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepin-3-yl)oxy)butanamido)-1-methyl-1H-pyrrole-2-carboxamido)phenyl)-1-methyl-1H-pyrrole-2-carboxamide	(S)-75-oxo-76- (4- (3-tosyl-2- (tosylmethyl)propanoyl)benzamido) 2,5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71-tetracosaoxa-74 azanonaheptacontan-79-oic acid	[141]
ADC Info	aU2023308528A1 ADC2 (DAR of 4)	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	PBD-butanamide derivative	6-Maleimidocaproic acid	[141]
ADC Info	aU2023279443A1 Example 3	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	U-030	AU2023279443A1, Example 4, Linker	[142]
ADC Info	aU2023279443A1 Example A2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	U-030	Undisclosed	[142]
ADC Info	aU2023279443A1 Example A10	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Ac-Exatecan	AU2023279443A1, Example A10, Linker	[142]
ADC Info	aU2023279443A1 Example A11	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	AU2023279443A1, Example A10, Linker	[142]
ADC Info	aU2023279443A1 Example A13	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	AU2023279443A1, Example A13, Linker	[142]
ADC Info	aU2023279443A1 Example A20	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Topo1 inhibitor A	AU2023279443A1, Example A12, Linker	[142]
ADC Info	aU2023279443A1 Example A23	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	RU20241285-23-payload	AU2023279443A1, Example A10, Linker	[142]
ADC Info	aU2023279443A1 Example A24	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	RU20241285-23-payload	AU2023279443A1, Example A24, Linker	[142]
ADC Info	cN117337196A Compound93	SCAPDL1xSCACD47	Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47)	DX-8951 derivative (DXd)	30kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA)	[143]
ADC Info	cN113943310A ADC-1	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	D-D9 payload	CN113943310A, ADC-1, Linker	[144]
ADC Info	cN113943310A ADC-2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	D-D10 payload	CN113943310A, ADC-1, Linker	[144]
ADC Info	cN113943310A ADC-3	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	D-D3 payload	CN113943310A, ADC-1, Linker	[144]
ADC Info	cN113943310A ADC-4	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	D-D4 payload	CN113943310A, ADC-1, Linker	[144]
ADC Info	cN113943310A ADC-5	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	D-D5 payload	CN113943310A, ADC-1, Linker	[144]
ADC Info	cN113943310A ADC-6	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	D-D6 payload	CN113943310A, ADC-1, Linker	[144]
ADC Info	cN113943310A ADC-7	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	D-D11 payload	CN113943310A, ADC-1, Linker	[144]
ADC Info	cN113943310A ADC-8	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	D-D12 payload	CN113943310A, ADC-1, Linker	[144]
ADC Info	cN113943310A ADC-9	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	D-D14 payload	CN113943310A, ADC-1, Linker	[144]
ADC Info	cN113943310A ADC-10	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	D-D1 payload	CN113943310A, ADC-1, Linker	[144]
ADC Info	cN113943310A ADC-14	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	compound 4	CN113943310A, ADC-12, Linker	[144]
ADC Info	cN113943310A ADC-15	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	compound 5	CN113943310A, ADC-12, Linker	[144]
ADC Info	cN113943310A ADC-19	Cetuximab	Epidermal growth factor receptor (EGFR)	D-D3 payload	CN113943310A, ADC-1, Linker	[144]
ADC Info	cN113943310A ADC-20	Cetuximab	Epidermal growth factor receptor (EGFR)	D-D7 payload	CN113943310A, ADC-1, Linker	[144]
ADC Info	wO2024239281A1 C031	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-Gly amide	Mal-PEG-Ala-Ala-Ala linker	[145]
ADC Info	wO2024239281A1 C039	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-Gly amide	Mal-PEG-Val-Ala linker	[145]
ADC Info	wO2024239281A1 C054	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-aminoethoxy	Mal-PEG-Val-Ala linker	[145]
ADC Info	wO2024239281A1 C060	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-carbamate (aminoethyl)	Mal-PEG-Val-Ala linker	[145]
ADC Info	wO2024239281A1 C078	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-L-Ala amide	Maleimide-PEG-L-Valine linker	[145]
ADC Info	wO2024239281A1 C084	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-Gly amide	Bis-maleimide-PEG linker	[145]
ADC Info	wO2024239281A1 C084C	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-Gly amide	WO2024239281A1, C084C, Linker	[145]
ADC Info	wO2024239281A1 C112	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-Gly amide	WO2024239281A1, C112, Linker	[145]
ADC Info	wO2024239281A1 C117	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-aminoethoxy	WO2024239281A1, C117, Linker	[145]
ADC Info	wO2024239281A1 C144	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-Gly amide	WO2024239281A1, C144, Linker	[145]
ADC Info	wO2024239281A1 C158	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-Gly amide	WO2024239281A1, C158, Linker	[145]
ADC Info	wO2024239281A1 C193	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	(R)-5- (3- ((S)-2- ((S)-2-amino-3-methylbutanamido)propanamido)-4- hydroxyphenyl)-4- (2- ((6S,9R,11R)-6- ((S)-sec-butyl)-9-isopropyl-2,3,3,8-tetramethyl-4,7,13-trioxo-12-oxa-2,5,8-triazatetradecan-11-yl)thiazole-4-carboxamido)pentanoic acid	WO2024239281A1, C193, Linker	[145]
ADC Info	wO2024239281A1 C200	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	(R)-5- (3- ((S)-2- ((S)-2-amino-3-methylbutanamido)propanamido)-4- hydroxyphenyl)-4- (2- ((6S,9R,11R)-6- ((S)-sec-butyl)-9-isopropyl-2,3,3,8-tetramethyl-4,7,13-trioxo-12-oxa-2,5,8-triazatetradecan-11-yl)thiazole-4-carboxamido)pentanoic acid	WO2024239281A1, C200, Linker	[145]
ADC Info	wO2024239281A1 C207	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-aminoethoxy	WO2024239281A1, C207, Linker	[145]
ADC Info	wO2024239281A1 C207C	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-aminoethoxy	WO2024239281A1, C207C, Linker	[145]
ADC Info	wO2024239281A1 C213	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-phenoxy-Ala	Maleimide-PEG-L-Valine linker	[145]
ADC Info	wO2024239281A1 C218	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	4- ((S)-2-aminopropanamido)benzyl (2- ((S)-4,11-diethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl)oxy)ethyl)carbonate	WO2024239281A1, C218, Linker	[145]
ADC Info	wO2024239281A1 C225	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	2- (( (S)-4,11-diethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl)oxy)ethyl (4- ((S)-2-aminopropanamido)benzyl)carbamate	Maleimide-PEG-L-Valine linker	[145]
ADC Info	wO2024239281A1 C230	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-phenoxy-PEG2-Ala	Maleimide-PEG-L-Valine linker	[145]
ADC Info	wO2024239281A1 C237	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-PEG2-Ala	Maleimide-PEG-L-Valine linker	[145]
ADC Info	wO2024239281A1 C257	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-aminoethoxy	WO2024239281A1, C257, Linker	[145]
ADC Info	wO2024239281A1 C263	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-aminoethoxy	WO2024239281A1, C263, Linker	[145]
ADC Info	wO2024239281A1 C266	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-aminoethoxy	WO2024239281A1, C266, Linker	[145]
ADC Info	wO2024239281A1 C266C	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-aminoethoxy	WO2024239281A1, C266C, Linker	[145]
ADC Info	wO2024239281A1 C269	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-aminoethoxy	WO2024239281A1, C269, Linker	[145]
ADC Info	wO2024239281A1 C269C	Vandortuzumab	Metalloreductase STEAP1 (STEAP1)	Exatecan-aminoethoxy	WO2024239281A1, C269C, Linker	[145]
ADC Info	wO2024181570A1 ADC5	Antibody 1	Syndecan-1 (SDC1)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[146]
ADC Info	wO2024181570A1 ADC6	Antibody 1	Syndecan-1 (SDC1)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[146]
ADC Info	wO2024105206A1 3i-5657	TPP-5657	Undisclosed	Ac-Exatecan	32p-Avelu Linker	[120]
ADC Info	wO2024105206A1 3k-2658	TPP-2658	Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A)	Ac-Exatecan	32p-Avelu Linker	[120]
ADC Info	wO2024105206A1 5k-2658	TPP-2658	Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A)	6i-5657 Payload	3i-5657 Linker	[120]
ADC Info	wO2024105206A1 6i-5657	TPP-5657	Undisclosed	6i-5657 Payload	3i-5657 Linker	[120]
ADC Info	wO2024105206A1 6k-2658	TPP-2658	Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A)	6i-5657 Payload	3i-5657 Linker	[120]
ADC Info	wO2024105206A1 8i-5657	TPP-5657	Undisclosed	Mdo-cpt	Undisclosed	[120]
ADC Info	wO2024105206A1 10i-5657	TPP-5657	Undisclosed	Ac-Exatecan	CHH0187, 10i-5657, Linker	[120]
ADC Info	wO2015115091A1 ADCLP-10	mAb42	Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)	DX-8951 derivative (DXd)	DBCO-PEG4-GGFG-aminol	[147]
ADC Info	sWY2110-GGFG-DXD ADC	SWY2110	Epidermal growth factor receptor (EGFR)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[148]
ADC Info	dDR1 ADC	undisclosed	Epithelial discoidin domain-containing receptor 1 (DDR1)	DX-8951 derivative (DXd)	Mc-Gly-Gly-Phe-Gly	[149]
ADC Info	bCN-linker-Dxd1	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	BCN-linker	[150]
ADC Info	bCN-linker-Dxd2	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	BCN-linker	[150]
ADC Info	bCN-linker-Dxd3	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	BCN-linker	[150]
ADC Info	bCN-linker-Dxd4	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	BCN-linker	[150]
ADC Info	lT4212552T ADC-3	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	Mc-Gly-Gly-Phe-Gly	[151]
ADC Info	lT4212552T ADC5	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	LT4212552T-ADC-5-LINKER	[151]
ADC Info	lT4212552T ADC7	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	LT4212552T-ADC-7-LINKER	[151]
ADC Info	lT4212552T ADC8	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	LT4212552T-ADC-8-LINKER	[151]
ADC Info	lT4212552T ADC9	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	LT4212552T-ADC-9-LINKER	[151]
ADC Info	lT4212552T ADC10	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC10 payload	LT4212552T-ADC-10-LINKER	[151]
ADC Info	lT4212552T ADC13	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC13 payload	Mc-Gly-Gly-Phe-Gly	[151]
ADC Info	lT4212552T ADC15	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC37 payload	Undisclosed	[151]
ADC Info	lT4212552T ADC16	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC37 payload	Undisclosed	[151]
ADC Info	lT4212552T ADC17	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC37 payload	LT4212552T-ADC-17-LINKER	[151]
ADC Info	lT4212552T ADC18	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC37 payload	LT4212552T-ADC-17-LINKER	[151]
ADC Info	lT4212552T ADC19	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC37 payload	LT4212552T-ADC-19-LINKER	[151]
ADC Info	lT4212552T ADC20	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC37 payload	LT4212552T-ADC-19-LINKER	[151]
ADC Info	lT4212552T ADC21	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC37 payload	LT4212552T-ADC-21-LINKER	[151]
ADC Info	lT4212552T ADC22	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC37 payload	LT4212552T-ADC-21-LINKER	[151]
ADC Info	lT4212552T ADC24	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC25 payload	LT4212552T-ADC-24-LINKER	[151]
ADC Info	lT4212552T ADC25	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC25 payload	LT4212552T-ADC-24-LINKER	[151]
ADC Info	lT4212552T ADC26	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[151]
ADC Info	lT4212552T ADC27	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[151]
ADC Info	lT4212552T ADC28	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[151]
ADC Info	lT4212552T ADC29	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[151]
ADC Info	lT4212552T ADC30	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[151]
ADC Info	lT4212552T ADC31	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[151]
ADC Info	lT4212552T ADC36	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC37 payload	LT4212552T-ADC-36-LINKER	[151]
ADC Info	lT4212552T ADC37	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC37 payload	LT4212552T-ADC-36-LINKER	[151]
ADC Info	lT4212552T ADC41	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Topo1 inhibitor B	Mc-Gly-Gly-Phe-Gly	[151]
ADC Info	lT4212552T ADC42	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Topo1 inhibitor B	Mc-Gly-Gly-Phe-Gly	[151]
ADC Info	lT4212552T ADC43	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	LT4212552T-ADC-6-LINKER	[151]
ADC Info	lT4212552T ADC44	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	HK40112172A+Antibody-drug conjugate (44)+Linker	[151]
ADC Info	lT4212552T ADC46	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[151]
ADC Info	lT4212552T ADC47	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[151]
ADC Info	lT4212552T ADC49	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	LT4212552T ADC49 payload	Mc-Gly-Gly-Phe-Gly	[151]
ADC Info	tW202506738A C-009	undisclosed	Undisclosed	TW202506738A-C-009-PAYLOAD	TW202506738A-C-009-LINKER	[152]
ADC Info	tW202506738A C-020	undisclosed	Undisclosed	TW202506738A-C-009-PAYLOAD	TW202506738A-C-020-LINKER	[152]
ADC Info	tW202506738A C-096	undisclosed	Undisclosed	Topo1 inhibitor E	TW202506738A-C-096-LINKER	[152]
ADC Info	tW202506738A C-111	undisclosed	Undisclosed	Topo1 inhibitor E	TW202506738A-C-111-LINKER	[152]
ADC Info	tW202506738A C-133	undisclosed	Undisclosed	Topo1 inhibitor E	TW202506738A-C-133-LINKER	[152]
ADC Info	tW202506738A C-155	undisclosed	Undisclosed	Topo1 inhibitor E	TW202506738A-C-155-LINKER	[152]
ADC Info	tW202506738A C-168	undisclosed	Undisclosed	Topo1 inhibitor E	TW202506738A-C-168-LINKER	[152]
ADC Info	tW202506738A C-172	undisclosed	Undisclosed	Topo1 inhibitor E	TW202506738A-C-172-LINKER	[152]
ADC Info	tW202506738A C-182	undisclosed	Undisclosed	Topo1 inhibitor G	TW202506738A-C-182-LINKER	[152]
ADC Info	tW202506738A C-186	undisclosed	Undisclosed	Topo1 inhibitor G	TW202506738A-C-186-LINKER	[152]
ADC Info	eP4487874A1-12	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	EP4487874A1-12linker	[153]
ADC Info	eP4487874A1-14	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	EP4487874A1-14linker	[153]
ADC Info	38354417 T-DL1	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	FD1	MT-GGFG-AM	[154]
ADC Info	38354417 T-DL3	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	FD2	MT-GGFG-AM	[154]
ADC Info	38354417 T-DL4	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	FD3	MT-GGFG-AM	[154]
ADC Info	38354417 T-DL9	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	10NH2-11F-Camptothecin	MT-GGFG-AM	[154]
ADC Info	38354417 T-DL5	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	FD5	MT-GGFG-AM	[154]
ADC Info	38354417 T-DL6	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	FD5	Mc-Gly-Gly-Phe-Gly	[154]
ADC Info	38354417 T-DL11	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	FD5	MT-GGFG-AM	[154]
ADC Info	38354417 T-DL13	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	FD6	MT-GGFG-AM	[154]
ADC Info	38354417 T-DL14	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	FD7	MT-GGFG-AM	[154]
ADC Info	38354417 T-DL7	Trastuzumab	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	DX-8951 derivative (DXd)	MT-GGFG-AM	[154]
ADC Info	mGC028	Anti-ADAM9 antibody	ADAM9	Exatecan	Bicyclononyne carbamoyl sulfamide Val-Ala-PABC
ADC Info	aK138D1	Patritumab	HER3	DXd	Mc-Ala-Ala-Ala
ADC Info	sHR-1681	Anti-HER3/c-Met bsAb	HER3; c-Met	TOP1 inhibitor	Undisclosed
ADC Info	sKB445	Anti-CDH3 antibody	CDH3	KL610348	A cleavable linker
ADC Info	aDCE-D01	Anti-MRC2 antibody	MRC2	P1021	A cleavable linker
ADC Info	zPC-21	Anti-ROR1 mAb	ROR1	HC74	A cleavable linker
ADC Info	eSG406	Anti-TROP2 mAb	TROP2	Exatecan	A cleavable linker
ADC Info	yL217	Anti-CDH17 antibody	CDH17	YL0010014	VK*G-NHCH2-O linker
ADC Info	mHB046C	undisclosed	Undisclosed	TOP1 inhibitor	A cleavable linker
ADC Info	hS-20108	Anti-SEZ6 antibody	SEZ6	TOP1 inhibitor	Undisclosed
ADC Info	sIM 0686	Anti-FGFR2b IgG1 antibody	FGFR2	CPT116	A cleavable linker
ADC Info	sIBP-A19	SIBP-A12	FRα	DXd	Mc-VASGFG
ADC Info	aK146D1	Anti-nectin-4/TROP2 bsAb	nectin-4; TROP2	DXd	Mc-Ala-Ala-Ala
ADC Info	bL-M09D1	Anti-CEA mAb	CEA	Ed-04	Gly-Mal-Gly-Gly-Phe-Gly
ADC Info	sIBP-A18	Anti-CLDN18.2 antibody	CLDN18.2	DXd	Mc-VASGFG
ADC Info	sKB518	Anti-PTK7 antibody	PTK7	KL610348	Kthiol (pyrimidine-thiol) GGFG linker
ADC Info	mRG007	Anti-CDH17 mAb	CDH17	Exatecan	Undisclosed
ADC Info	xNW28012	Anti-tissue factor antibody	tissue factor	YL0010014	VK*G-NHCH2-O linker
ADC Info	lY4175408	Anti-PTK7 mAb	PTK7	Exatecan	A proprietary polysarcosine hydrophobicity linker
ADC Info	hDM2020	Anti-FGFR2 antibody	FGFR2	TOP1 inhibitor	A cleavable linker
ADC Info	hDM2012	Anti-Muc17 antibody	Muc17	TOP1 inhibitor	A cleavable linker
ADC Info	rC278	Anti-CDCP1 antibody	CDCP1	TOP1 inhibitor	A cleavable linker
ADC Info	aLX2004	Anti-EGFR antibody	EGFR	TOP1 inhibitor	Undisclosed
ADC Info	iCP-B794	Anti-B7H3 antibody	B7-H3	TOP1 inhibitor	A cleavable linker
ADC Info	bNT3212	Anti-EGFR/HER3 bsAb	EGFR; HER3	TOP1 inhibitor	A cleavable linker
ADC Info	dB-1317	Anti-ADAM9 antibody	ADAM9	TOP1 inhibitor	Undisclosed
ADC Info	bG-C0902	Anti-EGFR/c-Met bsAb	EGFR; c-Met	TOP1 inhibitor	A cleavable linker
ADC Info	bNT329	Anti-CA19-9 antibody	CA19-9	YL0010014	VK*G-NHCH2-O linker
ADC Info	vBC103	Anti-Nectin-4/TROP2 bispecific VHH-Fc	nectin-4; TROP2	TOP1 inhibitor	Undisclosed
ADC Info	fS001	undisclosed	Undisclosed	TOP1 inhibitor	A cleavable linker
ADC Info	sofetabart mipitecan	Sofetabart	FRα	Exatecan	Mal-Polysarcosine10-Val-Ala-PABC
ADC Info	7MW4911	Mab0727	CDH17	Mtoxin	A cleavable disulfide linker
ADC Info	mRG006	Anti-GPC3 mAb	GPC3	Novel TOP1 inhibitor	MCC-AAQ
ADC Info	sKB571	Anti-EGFR/c-Met bsAb	EGFR; c-Met	KL610348	Kthiol (pyrimidine-thiol) AAA linker
ADC Info	fH-006	MG2303	B7-H3; EGFR	SHR9265	Mc-Gly-Gly-Phe-Gly
ADC Info	sYS6043	Anti-B7H3 antibody	B7-H3	JS-1	Mc-Gly-Gly-Phe-Gly
ADC Info	genSci139	Anti-EGFR/HER2 bsAb	EGFR; HER2	GSC5181	A cleavable linker
ADC Info	dS3790a	Anti-CD37 mAb	CD37	DXd	Mc-Gly-Gly-Phe-Gly
ADC Info	genSci143	Anti-B7H3/PSMA bsAb	B7-H3; PSMA	GSC5181	A cleavable linker
ADC Info	genSci140	Anti-FRα antibody	FRα	GSC5181	A cleavable linker
ADC Info	sKB500	Anti-B7H3 antibody	B7-H3	KL610348	A cleavable linker
ADC Info	hS-20110	Anti-CDH17 antibody	CDH17	HS-9265	Undisclosed
ADC Info	tQB6411	Anti-EGFR/c-Met bsAb	EGFR; c-Met	2-DDDX-d	A cleavable linker
ADC Info	6-Dec	(undisclosed)	PTK7	CPT113	Highly stable yet cleavable linker
ADC Info	sKB105	Anti-ITGB6 full human IgG1	ITGB6	TOP1 inhibitor	Kthiol (pyrimidine-thiol) oligopeptide linker
ADC Info	sHR-4394	Anti-PSMA mAb	PSMA	SHR9265	A cleavable linker
ADC Info	bCG034	Anti-B7H3/PTK7 bsAb	B7-H3; PTK7	BCPT02	Hydrophilic, protease-cleavable linker
ADC Info	lCB02A	HClaudin18.2	CLDN18.2	PR301839	Undisclosed
ADC Info	bMS-986490	Anti-CEA antibody	CEA	TOP1 inhibitor	Undisclosed
ADC Info	hS-20105	Anti-TROP2 antibody	TROP2	TOP1 inhibitor	A cleavable linker
ADC Info	iBI133	Anti-HER3 mAb	HER3	Exatecan	A cleavable linker
ADC Info	sGN-35C	Brentuximab	CD30	AMDCPT	A cleavable linker
ADC Info	sHR-7631	Anti-LIV-1 mAb	LIV-1	SHR9265	Undisclosed
ADC Info	fZ-AD005	Anti-DLL3 antibody	DLL3	DXd	Mc-Val-Ala-PABC double self-immolative linker
ADC Info	sIBP-A17	Anti-HER2 antibody	HER2	DXd	Mc-VASGFG
ADC Info	sYS6023	Anti-HER3 mAb	HER3	Self-developed TOP1 inhibitor	Undisclosed
ADC Info	iBI3009	Anti-DLL3 mAb	DLL3	NT1	Undisclosed
ADC Info	hS-20124	Anti-CDH6 antibody	CDH6	SHR9265	Undisclosed
ADC Info	m3554	Anti-GD2 antibody	GD2	Exatecan	Mal-glucuronide-PABC
ADC Info	aLK201	Anti-FGFR2 mAb	FGFR2	Exatecan	A cleavable linker
ADC Info	aLK202	Anti-EGFR/c-Met bsAb	EGFR; c-Met	Exatecan	Undisclosed
ADC Info	sIM0505	Anti-CDH6 antibody	CDH6	CPT116	A cleavable linker
ADC Info	iBI3014	Anti-PDL1/TROP2 bsAb	PDL1; TROP2	NT1	A cleavable linker
ADC Info	sHR-3792	Anti-EGFR/Muc1 bsAb	EGFR; Muc1	TOP1 inhibitor	A cleavable linker
ADC Info	aZD4360	Anti-CLDN18.2 antibody	CLDN18.2	TOP1 inhibitor	Undisclosed
ADC Info	sYS6045	Anti-HER2 antibody	HER2	TOP1 inhibitor	Undisclosed
ADC Info	qLS5133	Anti-CDH6 antibody	CDH6	QLS6916	A cleavable linker
ADC Info	aZD4512	Anti-CD22 antibody	CD22	TOP1 inhibitor	A cleavable linker
ADC Info	aLE.P03	H1L1	CLDN1	Exatecan	Mc-Gly-Gly-Phe-Gly
ADC Info	sIM0609	Anti-CDH17 antibody	CDH17	CPT116	A cleavable linker
ADC Info	yLSH003	Anti-tissue factor antibody	tissue factor	TOP1 inhibitor	A cleavable linker
ADC Info	bC2027	Anti-GPC3 antibody	GPC3	TOP1 inhibitor	A cleavable linker
ADC Info	kIVU-107	Anti-PTK7 IgG1 mAb	PTK7	Exatecan	Undisclosed
ADC Info	aDCX-020	undisclosed	Undisclosed	TOP1 inhibitor	A cleavable linker
ADC Info	jS212	Anti-EGFR/HER3 bsAb	EGFR; HER3	Exatecan	A cleavable linker
ADC Info	sIM0610	Anti-EGFR/c-Met bsAb	EGFR; c-Met	TOP1 inhibitor	A cleavable hydrophilic linker?
ADC Info	m7437	Anti-Ly6E antibody	Ly6E	Exatecan	Undisclosed
ADC Info	qLS5316	Anti-EGFR/c-Met bsAb	EGFR; c-Met	QLS6916	A cleavable linker
ADC Info	jSKN027	Anti-PDL1/TVEGFR2 bsAb	PDL1; VEGFR2	TOP1 inhibitor	A cleavable linker
ADC Info	bG-C0979	Anti-ADAM9 antibody	ADAM9	TOP1 inhibitor	Undisclosed

References

Ref 1	AMB302/GR1017, an antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor shows therapeutic potency in orthotopic glioblastoma PDX and bladder cancer models with FGFR3-TACC3 fusion. Cancer Res (2023) 83 (7_Supplement): 2634.
Ref 2	Introduction to basic information on ADC drug Trastuzumab rezetecan.
Ref 3	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Ref 4	Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
Ref 5	Mabwell biopharmaceutical company product pipeline
Ref 6	Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
Ref 7	A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Ref 8	Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate.
Ref 9	Exelixis biotechnology company product pipeline
Ref 10	Clinical Trial Application for 7MW3711 - an Innovative Drug Developed by Mabwell's ADC Platform, Accepted by NMPA.
Ref 11	Development of Novel Antibody-Camptothecin Conjugates. Mol Cancer Ther. 2021 Feb;20(2):329-339.
Ref 12	Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates. Drug Deliv. 2021 Dec;28(1):2603-2617.
Ref 13	Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity. Biomed Pharmacother. 2023 Jan;157:114047.
Ref 14	Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2012 Jan;11(1):224-34.
Ref 15	A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. Mol Ther. 2022 Aug 3;30(8):2785-2799.
Ref 16	Modified taxols .6. preparation of water-soluble prodrugs of taxol. J Nat Prod. 1991;54(6):1607-1611.
Ref 17	Zai lab announces strategic partnership and global license agreement with medilink therapeutics for a next generation antibody-drug conjugate program in oncology
Ref 18	Biokin pharma Prospectus; 2022
Ref 19	Huaota biopharmaceutical company product pipeline
Ref 20	DAC biotechnology company product pipeline
Ref 21	An innovative site-specific dual-payload antibody drug conjugate (dpADC) combining a novel Topo1 inhibitor and an immune agonist delivers a strong immunogenic cell death (ICD) and antitumor response in vitro and in vivo. Cancer Res (2023) 83 (7_Supplement): 2640.
Ref 22	HER2-targeted DEP SN-38 ADC outperforms in HER2+ human cancer model (ASX announcement); 2023
Ref 23	Diazaborines Are a Versatile Platform to Develop ROS-Responsive Antibody Drug Conjugates*. Angew Chem Int Ed Engl. 2021 Dec 1;60(49):25914-25921. doi: 10.1002/anie.202109835. Epub 2021 Nov 5.
Ref 24	Optimal cleavable linker for antibody-SN-38 conjugates for cancer therapy: Impact of linker's stability on efficacy. Cancer Res (2012) 72 (8_Supplement): 2526.
Ref 25	IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma. Mol Cancer Ther. 2018 Jan;17(1):150-160. doi: 10.1158/1535-7163.MCT-17-0354. Epub 2017 Nov 13.
Ref 26	Antibody-SN-38 immunoconjugates with a CL2A linker.
Ref 27	Introduction to basic information on ADC drug hA19-SN-38 antibody-drug conjugate - Immunomedics.
Ref 28	Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. Sci Rep. 2017 Sep 6;7(1):10735. doi: 10.1038/s41598-017-11255-4.
Ref 29	Daiichi-Sankyo showcases latest research towards creating new standards of care for patients with cancer with data at ASCO and EHA; 25 May 2023.
Ref 30	Xiling yuan pharmaceutical company product pipeline
Ref 31	The preclinical pharmacology of PRO1102, a novel exatecan-based HER2-directed antibody-drug conjugate with robust anti-tumor activity. Cancer Res (2022) 82 (12_Supplement): 1758.
Ref 32	Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Pharmaceuticals (Basel). 2021 Mar 9;14(3):247. doi: 10.3390/ph14030247.
Ref 33	STRO-003 is a novel ROR1-targeted ADC for breast and lung cancer. Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.1191.
Ref 34	HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models. Cancer Res (2023) 83 (7_Supplement): 2660.
Ref 35	Nanovalent pharmaceuticals product pipeline
Ref 36	ADC review NV103
Ref 37	An investigational next generation ADC (DAN-311) is highly effective in HER2-low breast cancer models. Cancer Res (2022) 82 (4_Supplement): P2-13-09.
Ref 38	ZW251, a novel glypican-3-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload. Cancer Res (2023) 83 (7_Supplement): 2658.
Ref 39	ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload. Cancer Res (2023) 83 (7_Supplement): 1533.
Ref 40	Introduction to basic information on ADC drug AMB-101
Ref 41	Sutro biopharmaceutical company product pipeline
Ref 42	Introduction to basic information on ADC drug SIBP-A13
Ref 43	A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells. MAbs. 2023 Jan-Dec;15(1):2220466. doi: 10.1080/19420862.2023.2220466.
Ref 44	Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discov. 2023 Apr 3;13(4):950-973. doi: 10.1158/2159-8290.CD-22-1368.
Ref 45	Antibody-Assisted Delivery of a Peptide-Drug Conjugate for Targeted Cancer Therapy. Mol Pharm. 2019 Jan 7;16(1):165-172. doi: 10.1021/acs.molpharmaceut.8b00924. Epub 2018 Dec 17.
Ref 46	Antibody drug conjugates; 2023-07-06.
Ref 47	Antitumor compound, and preparation method therefor and use thereof; 2022-04-07.
Ref 48	Camptothecin derivative and ligand-drug conjugate thereof; 2022-04-21.
Ref 49	Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2012 Jan;11(1):224-34. doi: 10.1158/1535-7163.MCT-11-0632. Epub 2011 Oct 28.
Ref 50	Innoventbio 2022 Annual Performance Report.
Ref 51	Uses of antibody-drug conjugates
Ref 52	TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Mol Cancer Ther. 2022 Jul 5;21(7):1090-1102.
Ref 53	ADC review: basic information about Epratuzumab-SN-38.
Ref 54	MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
Ref 55	Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors
Ref 56	Generation and Characterization of SORT1-Targeted Antibody-Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor
Ref 57	Anti-tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models
Ref 58	An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL)
Ref 59	Identification of CD66c as a potential target in gastroesophageal junction cancer for antibody-drug conjugate development
Ref 60	Generation of a Novel SORT1×HER2 Bispecific Antibody-Drug Conjugate Targeting HER2-Low-Expression Tumor
Ref 61	Evaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody-Drug Conjugates with Different Payloads
Ref 62	Design, Synthesis, and Evaluation of Camptothecin-Based Antibody-Drug Conjugates with High Hydrophilicity and Structural Stability
Ref 63	Harnessing acylhydrazone-oxime exchange reaction to achieve diverse synthesis of glycosite-specific antibody-drug conjugates
Ref 64	An antibody-drug conjugate targeting soluble and membrane-bound TGFα is effective against pancreatic tumors
Ref 65	Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody-Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models
Ref 66	In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment
Ref 67	Reprogramming the Tumor Immune Microenvironment with ICAM-1-Targeted Antibody-Drug Conjugates and B7-H3-CD3 Bispecific Antibodies
Ref 68	ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma
Ref 69	OBI-902, a novel TROP2 targeted antibody-drug conjugate via GlycOBI® platform, has favorable pharmacokinetics and sustained antitumor activities in challenging solid tumors
Ref 70	MUC1*-deruxtecan kills tumors that have acquired resistance to trastuzumab containing therapeutics
Ref 71	A next generation ADC: AR153, pH-dependent anti-B7H3 MMAE
Ref 72	Preclinical development of TJ101, a potent bispecific ADC targeting EGFR and B7-H3 for the treatment of solid cancers
Ref 73	Discovery and characterization of a novel LRRC15-targeting antibody drug conjugate (ADC) for the treatment of solid tumors
Ref 74	Preclinical development of MHB042C: A next-generation anti-c-Met ADC conjugating VHH-Fc fusion protein with a novel topoisomerase I inhibitor
Ref 75	Preclinical evaluation of LM-350: An innovative anti-CDH17 antibody drug conjugate for gastrointestinal cancer therapy
Ref 76	DB-1418, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, demonstrates superior and broad antitumor efficacy and favorable safety in preclinical models
Ref 77	Preclinical characterization of AZD0516, a novel STEAP2 antibody-drug conjugate (ADC) for the treatment of prostate cancer
Ref 78	Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b-targeting ADC, for the treatment of FGFR2b-expressing cancer
Ref 79	ADCE-T02: A first-in-class topoisomerase-1 inhibitor based antibody drug conjugate against tissue factor demonstrates excellent preclinical efficacy and tolerability
Ref 80	Preclinical development of MHB009C: A novel anti-B7-H4 ADC with a potent topoisomerase I inhibitor
Ref 81	Improved tumor penetration and cytotoxic payload release with TD001, a novel PSMA-targeting ADC with optimized linker-payload composition, in PSMA-expressing CRPC CDX castrated mouse models
Ref 82	Novel hydrophilic CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical xenograft models
Ref 83	Preclinical development of YL242, a non-internalized antibody-drug conjugate (ADC) targeting soluble VEGF for treatment of solid tumors
Ref 84	BGB-C354, a novel B7H3 ADC with high DAR stability and strong bystander effect, demonstrates robust antitumor activity in preclinical models
Ref 85	Efficacy of novel urokinase plasminogen activator receptor-associated protein targeted antibody-drug conjugates in patient-derived xenografts of soft tissue sarcoma
Ref 86	Preclinical development of MHB048C: A novel anti-PSMA ADC with a potent topoisomerase I inhibitor
Ref 87	JSKN022, a first in class multi-specific ADC targeting PD-L1 and ITGB6/8 with an innovative DNA topoisomerase I inhibitor demonstrates encouraging efficacy in preclinical models
Ref 88	SYS6041, a next-generation Folate Receptor α-targeted antibody-drug conjugates for the treatment of FRα-expressing malignancies
Ref 89	PF-08046876: A new camptothecin antibody-drug conjugate directed to integrin beta-6 with potent antitumor activity in multiple preclinical solid tumor models
Ref 90	Discovery of HDM2017, a CDH17-targeting ADC for colorectal cancers
Ref 91	BG-C477, a novel topoisomerase 1 inhibitor-based ADC, exhibits antitumor activity in carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing preclinical models
Ref 92	A phase 1 first-in-human study evaluating safety, pharmacokinetics, and efficacy of ABBV-291, a CD79b-targeting antibody-drug conjugate, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Ref 93	A dose escalation and cohort expansion phase I/IIa study of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors
Ref 94	Antibody-drug conjugates
Ref 95	A drug conjugate and its preparation method and application
Ref 96	Prodrugs of topoisomerase I inhibitor for ADC conjugations and methods of use thereof
Ref 97	Antibody-drug conjugate intermediates carrying irinotecan and C-lock site-specific conjugation groups, conjugation methods and antibody-drug conjugates
Ref 98	Antibody-drug conjugates and applications thereof
Ref 99	Antibody-drug conjugates and uses thereof
Ref 100	Antibody-drug conjugate
Ref 101	Anti-ROR1 antibodies and antibody conjugates, compositions comprising Anti-ROR1 antibodies or antibody conjugates, and methods of making and using Anti-ROR1 antibodies and antibody conjugates
Ref 102	Monoclonal antibodies targeting GPC3 and antibody-drug conjugates comprising the antibodies
Ref 103	Anti-TPBG/MET antibodies and uses thereof
Ref 104	CD70 antibody drug conjugates and methods of using the same
Ref 105	Camptothecin analogs conjugated to glutamine residues in proteins and their uses
Ref 106	Anti-cdh6 antibody - Dosing drug zygote
Ref 107	Anti-ROR1 antibodies and antibody conjugates, compositions comprising Anti-ROR1 antibodies or antibody conjugates, and methods of making and using Anti-ROR1 antibodies and antibody conjugates
Ref 108	DDX5 protein-binding camptothecin derivatives and prodrugs thereof
Ref 109	Anti-b7h3 antibody-drug conjugate and use thereof
Ref 110	Antibody drug conjugates
Ref 111	Antibody-drug conjugates and uses thereof
Ref 112	Ph-dependent Anti-sulfated glycosaminoglycan antibody and antibody-drug conjugate
Ref 113	Preparation method and application of antibody drug conjugate
Ref 114	Small-molecule active compounds and their antibody conjugates, preparation methods and medical uses
Ref 115	Antibody-drug conjugate and use thereof
Ref 116	Anti-MUC1 antibody-drug conjugate
Ref 117	Anti-ASCT2 antibodies and ADCs derived therefrom
Ref 118	Anti-CEA antibody drug conjugates and methods of use
Ref 119	Prodrugs of topoisomerase I inhibitor for ADC conjugations and methods of use thereof
Ref 120	Antibody-drug conjugates cleavable in a tumor microenvironment
Ref 121	Therapy for drug-resistant cancer by administration of anti-HER2 antibody/drug conjugate
Ref 122	Anti-CDH6 antibodies and anti-CDH6 antibody-drug conjugates
Ref 123	Antibody-drug conjugates employing novel linker-payload systems for enhanced targeting of cancer-associated antigens
Ref 124	Anti-HER2 antibody-drug conjugate
Ref 125	Antibody-drug conjugates and production thereof
Ref 126	CD44-specific antibodies and their antibody-drug conjugates
Ref 127	Antibody-drug conjugate compounds, and methods of use and treatment
Ref 128	Antibody-drug conjugates of N-oxacycloalkyl substituted camptothecin derivatives
Ref 129	Antibody-drug conjugates targeting phosphatidylinositol proteoglycan-3 and methods of use
Ref 130	Specific topoisomerase inhibitors and their use in antibody-drug conjugates and preparation methods
Ref 131	Antibody-drug conjugates
Ref 132	Binding molecules against FR alpha
Ref 133	Antibody-drug complexes
Ref 134	Intermediates of antibody-drug conjugates containing SN-38 and methods of preparation
Ref 135	Antibody drug conjugate loaded with binary toxins and its application
Ref 136	Oligosaccharide linkers, linker-payloads comprising the linkers, and glycan chain-remodeled antibody-drug conjugates, preparation methods and uses thereof
Ref 137	Drug conjugates of imidazoquinoline amine derivatives, compositions and methods thereof
Ref 138	Combination of antibody-drug conjugate and PARP1 selective inhibitor
Ref 139	Interleukin-13 receptor subunit alpha-2 antibody-drug conjugates and uses thereof
Ref 140	Activatable tyrosine-protein kinase membrane receptor (ROR) antibody-drug conjugates and uses thereof
Ref 141	Antibody-drug conjugates
Ref 142	Antibody-multidrug conjugate
Ref 143	PEGylated antibody hydroxyl-bearing drug conjugates
Ref 144	Deuterated camptothecin derivatives and their antibody-drug conjugates
Ref 145	Targeted treatment of prostate cancers and other tumors by an antibody-drug conjugate
Ref 146	Antibody-drug complexes containing anti-CD138 antibodies
Ref 147	Anti-HER2 antibody-drug conjugate
Ref 148	Uses of an antibody-drug conjugate
Ref 149	Antibody-drug conjugate DDR1-DXd and applications thereof
Ref 150	Acetal-based cleavable linkers
Ref 151	Anti-HER2 antibody-drug conjugate
Ref 152	Site-specific conjugation of antibodies
Ref 153	Antibody-drug conjugate precursor and intermediate for synthesis thereof
Ref 154	Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates

Target Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)